Fluid collection assemblies including at least one securement body

Information

  • Patent Grant
  • 12268627
  • Patent Number
    12,268,627
  • Date Filed
    Monday, January 3, 2022
    3 years ago
  • Date Issued
    Tuesday, April 8, 2025
    a month ago
  • CPC
  • Field of Search
    • CPC
    • A61F5/441
    • A61F5/442
    • A61F5/443
    • A61F5/451
    • A61F5/4408
    • A61F5/44
    • A61F5/455
    • A61F5/4404
    • A61F13/15
    • A61F13/56
    • A61F13/62
    • A61F13/64
    • A61F13/66
    • A61F13/581
    • A61F13/82
    • A61F2013/16
    • A61F2013/51097
    • A61F2013/5694
    • C09J2301/31
  • International Classifications
    • A61F5/451
    • A61F5/44
    • Term Extension
      6
Abstract
Embodiments disclosed herein include fluid collection assemblies with at least one securement body. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient. The at least one securement body includes at least one of a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, a plurality of suction cups, or at least one friction material exhibiting a coefficient of static friction that is greater than at least a portion of the at least one porous material.
Description
BACKGROUND

A patient may have limited or impaired mobility such that typical urination processes are challenging or impossible. For example, the patient may have surgery or a disability that impairs mobility. In another example, the patient may have restricted travel conditions such as those experience by pilots, drivers, and workers in hazardous areas. Additionally, fluid collection from the patient may be needed for monitoring purposes or clinical testing.


Bed pans and urinary catheters, such as a Foley catheter, may be used to address some of these circumstances. However, bed pans and urinary catheters have several problems associated therewith. For example, bed pans may be prone to discomfort, spills, and other hygiene issues. Urinary catheters be may be uncomfortable, painful, and may cause urinary tract infections.


Thus, users and manufacturers of fluid collection assemblies continue to seek new and improved devices, systems, and methods to collect urine.


SUMMARY

Embodiments disclosed herein include fluid collection assemblies with at least one securement body, fluid collection systems including the same, and methods of using the same. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient. The at least one securement body includes at least one of a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, a plurality of suction cups, or at least one friction material exhibiting a coefficient of static friction that is greater than at least a portion of the at least one porous material.


In an embodiment, a fluid collection system is disclosed. The fluid collection system includes a fluid storage container configured to hold one or more bodily fluids therein. The fluid collection system also includes a fluid collection assembly. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient. The at least one securement body includes at least one of a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, a plurality of suction cups, or at least one friction material exhibiting a coefficient of static friction that is greater than at least a portion of the at least one porous material. The fluid collection system further includes a vacuum source in fluid communication with the fluid storage container and the fluid collection assembly. The vacuum source is configured to draw the one or more bodily fluids from the fluid collection assembly and deposit the one or more bodily fluids in the fluid storage container via one or more conduits.


Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.



FIG. 1A is an isometric view of a fluid collection assembly, according to an embodiment.



FIG. 1B is a cross-sectional view of the fluid collection assembly taken along plane 1B-1B shown in FIG. 1A, according to an embodiment.



FIG. 1C is an enlarged cross-sectional schematic of a portion of the base, according to an embodiment.



FIGS. 1D to 1F are cross-sectional schematics of different bases that may be used with the fluid collection assembly, according to different embodiments.



FIG. 2 is a cross-sectional schematic of a fluid collection assembly, according to an embodiment.



FIG. 3A is an isometric view of a fluid collection assembly, according to an embodiment.



FIG. 3B is a cross-sectional schematic of the fluid collection assembly taken along plane 3B-3B shown in FIG. 3A, according to an embodiment.



FIG. 4A is an isometric view of a fluid collection assembly that includes at least one friction material, according to an embodiment.



FIG. 4B is a cross-sectional schematic of the fluid collection assembly taken along plane 4B-4B shown in FIG. 4A, according to an embodiment.



FIGS. 4C-4E are isometric views of different fluid collection assemblies that include the friction material disposed therein in different arrangements, according to different embodiments.



FIG. 5A is a cross-sectional schematic of a portion of a fluid collection assembly, according to an embodiment.



FIG. 5B is a cross-sectional schematic of a portion of a fluid collection assembly, according to an embodiment.



FIG. 6 is a block diagram of a system for fluid collection, according to an embodiment.





DETAILED DESCRIPTION

Embodiments disclosed herein include fluid collection assemblies with at least one securement body, fluid collection systems including the same, and methods of using the same. An example fluid collection assembly may include a male fluid collection assembly configured to receive one or more bodily fluids (e.g., urine, blood, sweat, etc.) from a male urethral opening or a female fluid collection assembly configured to receive the bodily fluids from a female urethral opening. The fluid collection assembly includes a fluid impermeable barrier that at least defines a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body. The securement body is disposed on one or more components of the fluid collection assembly and is configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of the patient. For example, the securement body may be disposed on one or more of at least a portion of the fluid impermeable barrier, at least a portion of the porous material that extends across the opening, or a base. Examples of securement bodies include a plurality of fibers extending from at least one exterior surface of the fluid collection assembly, a plurality of suction cups, or a friction material that exhibits a coefficient of friction that is greater than at least a portion of the porous material.


During use, the fluid collection assembly is positioned adjacent to or receives the urethral opening of the patient. The patient may discharge one or more bodily fluids and the fluid collection assembly may receive the bodily fluids. However, movement of the fluid collection assembly may prevent the fluid collection assembly from receiving all or substantially all of the bodily fluids that are discharged by the patient. For example, movement of the fluid collection assembly may cause bodily fluids to leak. The leaked bodily fluids may create patient discomfort by causing the skin of the patient to remain moist, creating unsanitary conditions, requiring cleaning of the patient, and causing embarrassment to the patient.


Some conventional fluid collection assemblies rely on chemical adhesives or contact between the thighs of the patient and the fluid impermeable barrier to maintain the position of the fluid collection assembly and prevent bodily fluid leaks. However, the chemical adhesives may be painful to remove from the patient since such chemical adhesives may be attached to hair and sensitive regions of the patient (e.g., the region about the urethral opening). Further, the contact between the thighs of the patient and the fluid impermeable barrier may be unable to maintain the position of the fluid collection assembly because the patient is too thin (e.g., has gaps between the thighs that prevent contact with the fluid impermeable barrier) or the patient moves. The fluid collection assemblies that include at least one securement body (e.g., the plurality of fibers, the friction material, and/or the plurality of suction cups) are improvements over such conventional fluid collection assemblies. In an example, the securement body may engage the patient to limit movement of the fluid collection assembly but, unlike chemical adhesives, the securement body may be easily removed when certain forces are applied thereto. Further, the securement body may maintain the position of the fluid collection assembly even when the patient is too thin for the thighs of the patient to contact the fluid collection assembly and/or when the patient moves.



FIG. 1A is an isometric view of a fluid collection assembly 100, according to an embodiment. FIG. 1B is a cross-sectional view of the fluid collection assembly 100 taken along plane 1B-1B shown in FIG. 1A, according to an embodiment. The fluid collection assembly 100 is an example of a male fluid collection assembly though, in some embodiments, the fluid collection assembly 100 may be used to receive bodily fluids from a female urethral opening. The fluid collection assembly 100 includes a sheath 102 and a base 104. The base 104 is configured to be attached (e.g., permanently attached or configured to be permanently attached) to the sheath 102. The base 104 is also configured to be attached to the region about the urethral opening (e.g., penis) of the patient. The base 104 includes at least one securement body 106.


The sheath 102 includes a fluid impermeable barrier 108 that is at least partially formed from a first panel 110 and a second panel 112. The first panel 110 and the second panel 112 may be attached or integrally formed together (e.g., exhibits single piece construction). In an embodiment, as illustrated, the first panel 110 and the second panel 112 are distinct sheets. The fluid impermeable barrier 108 also defines a chamber 114 between the first panel 110 and the second panel 112, an opening 116 at a first end region 120 of the sheath 102, and an fluid outlet 118 at a second end region 122 of the sheath 102. The sheath 102 also includes at least one porous material 115 disposed in the chamber 114.


The inner surface(s) 124 of the fluid impermeable barrier 108 (e.g., inner surfaces of the first and second panels 110, 112) at least partially defines the chamber 114 within the fluid collection assembly 100. The fluid impermeable barrier 108 temporarily stores the bodily fluids in the chamber 114. The fluid impermeable barrier 108 may be formed of any suitable fluid impermeable material(s), such as a fluid impermeable polymer (e.g., silicone, polypropylene, polyethylene, polyethylene terephthalate, neoprene, a polycarbonate, etc.), a metal film, natural rubber, another suitable material, or combinations thereof. As such, the fluid impermeable barrier 108 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 108. In an example, the fluid impermeable barrier 108 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 108 may be formed of a hydrophobic material that defines a plurality of pores. At least one or more portions of at least an outer surface 126 of the fluid impermeable barrier 108 may be formed from a soft and/or smooth material, thereby reducing chaffing.


In an embodiment, at least one of the first panel 110 or the second panel 112 is formed from an at least partially transparent fluid impermeable material, such as polyethylene, polypropylene, polycarbonate, or polyvinyl chloride. Forming at least one of the first panel 110 or the second panel 112 from an at least partially transparent fluid impermeable material allows a person (e.g., medical practitioner) to examiner the penis. In some embodiments, both the first panel 110 and the second panel 112 are formed from at least partially transparent fluid impermeable material. Selecting at least one of the first panel 110 or the second panel 112 to be formed from an at least partially transparent impermeable material allows the penis to be examined without detaching the entire fluid collection assembly 100 from the region about the penis. For example, the chamber 114 may include a penis receiving area 128 that is configured to receive the penis of the individual when the penis extends into the chamber 114. The penis receiving area 128 may be defined by at least the porous material 115 and at least a portion of the at least partially transparent material of the first panel 110 and/or the second panel 112. In other words, the porous material 115 is positioned in the chamber 114 such that the porous material 115 is not positioned between the penis and at least a portion of the transparent portion of the first panel 110 and/or second panel 112 when the penis is inserted into the chamber 114 through the opening 116. The porous material 115 is generally not transparent and, thus, the portion of the at least partially transparent material of the first panel 110 and/or the second panel 112 that defines the penis receiving area 128 forms a window which allows the person to view into the penis receiving area 128 and examine the penis.


The opening 116 defined by the fluid impermeable barrier 108 provides an ingress route for fluids to enter the chamber 114 when the penis is a buried penis and allow the penis to enter the chamber 114 (e.g., the penis receiving area 128) when the penis is not buried. The opening 116 may be defined by the fluid impermeable barrier 108 (e.g., an inner edge of the fluid impermeable barrier 108). For example, the opening 116 is formed in and extends through the fluid impermeable barrier 108 thereby enabling bodily fluids to enter the chamber 114 from outside of the fluid collection assembly 100.


The fluid impermeable barrier 108 defines an fluid outlet 118 sized to receive an conduit 130. The conduit 130 may be at least partially disposed in the chamber 114 or otherwise in fluid communication with the chamber 114 through the fluid outlet 118. The fluid outlet 118 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 130 thereby substantially preventing the bodily fluids from escaping the chamber 114. In an embodiment, the fluid outlet 118 may be formed from a portion of the first panel 110 and the second panel 112 that are not attached or integrally formed together. In such an embodiment, the fluid impermeable barrier 108 may not include a cap exhibiting a rigidity that is greater than the portions of the fluid impermeable barrier 108 thereabout which may facilitate manufacturing of the fluid collection assembly 100 may decreasing the number of parts that are used to form the fluid collection assembly 100 and may decrease the time required to manufacture the fluid collection assembly 100. The lack of the cap may make securing the conduit 130 to the fluid outlet 118 using interference fit to be difficult though, it is noted, attaching the conduit 130 to the fluid outlet 118 may still be possible. As such, the conduit 130 may be attached to the fluid outlet 118 (e.g., to the first and second panels 110, 112) using an adhesive, a weld, or otherwise bonding the fluid outlet 118 to the fluid outlet 118. Attaching the conduit 130 to the fluid outlet 118 may prevent leaks and may prevent the conduit 130 from inadvertently becoming detached from the fluid outlet 118. In an example, the conduit 130 may be attached to the fluid outlet 118 in the same manufacturing step that attaches the first and second panels 110, 112 together.


As previously discussed, the sheath 102 includes at least one porous material 115 disclosed in the chamber 114. The porous material 115 may direct the bodily fluids to one or more selected regions of the chamber 114, such as away from the penis and towards the fluid outlet 118. In an embodiment, the porous material 115 includes a fluid permeable membrane extending across the opening 116 and a fluid permeable support since the fluid permeable membrane may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support may be positioned such that the fluid permeable membrane is disposed between the fluid permeable support and the fluid impermeable barrier 108. As such, the fluid permeable support may support and maintain the position of the fluid permeable membrane. The fluid permeable membrane may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. The fluid permeable support may include any of the fluid permeable membrane materials disclosed above in a more dense or rigid form, a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure or an open cell foam, spun nylon fiber, a natural material (e.g., cotton, wool, silk, or combinations thereof), any other suitable material, or combinations thereof. In an embodiment, the porous material 115 may only include one of the fluid permeable membrane or the fluid permeable support. In an embodiment, the porous material 115 includes a first porous layer, a second porous layer, and a plurality of fibers forming a layer between the first and second layers.


In an embodiment, the porous material 115 may be configured to wick any bodily fluids away from the opening 116, thereby preventing the bodily fluids from escaping the chamber 114. The permeable properties referred to herein may be wicking, capillary action, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “wicking.” Such “wicking” may not include absorption of the bodily fluids into the wicking material. Put another way, substantially no absorption of the bodily fluids into the material may take place after the material is exposed to the bodily fluids and removed from the bodily fluids for a time. While no absorption is desired, the term “substantially no absorption” may allow for nominal amounts of absorption of the bodily fluids into the wicking material (e.g., absorbency), such as less than about 30 wt % of the dry weight of the porous material, less than 20 wt %, less than 15 wt %, less than 10 wt %, less than about 7 wt %, less than about 5 wt %, less than about 3 wt %, less than about 2 wt %, less than about 1 wt %, or less than about 0.5 wt % of the dry weight of the porous material. The wicking material may also wick the bodily fluids generally towards an interior of the chamber 114, as discussed in more detail below. In an embodiment, the porous material 115 may include at least one absorbent or adsorbent material.


In an embodiment, the porous material 115 may be a sheet. Forming the porous material 115 as a sheet may facilitate the manufacturing of the fluid collection assembly 100. For example, forming the porous material 115 as a sheet allows the first panel 110, the second panel 112, and the porous material 115 to each be sheets. During the manufacturing of the fluid collection assembly 100, the first panel 110, the second panel 112, and the porous material 115 may be stacked and then attached to each other in the same manufacturing step. For instance, the porous material 115 may exhibit a shape that is the same size or, more preferably, slightly smaller than the size of the first panel 110 and the second panel 112. As such, attaching the first panel 110 and the second panel 112 together along the outer edges thereof may also attach the porous material 115 to the first panel 110 and the second panel 112. The porous material 115 may be slightly smaller than the first panel 110 and the second panel 112 such that the first panel 110 and/or the second panel 112 extend around the porous material 115 such that the porous material 115 does not form a passageway through the fluid impermeable barrier 108 through which the bodily fluids may leak. Also, attaching the porous material 115 to the first panel 110 and/or the second panel 112 may prevent the porous material 115 from significantly moving in the chamber 114, such as preventing the porous material 115 from bunching together near the fluid outlet 118. In an example, the porous material 115 may be attached to the first panel 110 or the second panel 112 (e.g., via an adhesive) before or after attaching the first panel 110 to the second panel 112. In an example, the porous material 115 may merely be disposed in the chamber 114 without attaching the porous material 115 to at least one of the first panel 110 or the second panel 112. In an embodiment, as will be discussed in more detail below, the porous material 115 may exhibit shapes other than a sheet, such as a hollow generally cylindrical shape.


Generally, the sheath 102 is substantially flat when the penis is not in the penis receiving area 128 and the sheath 102 is resting on a flat surface. The sheath 102 is substantially flat because the fluid impermeable barrier 108 is formed from the first panel 110 and the second panel 112 instead of a generally tubular fluid impermeable barrier. Further, as previously discussed, the porous material 115 may be a sheet, which also causes the sheath 102 to be substantially flat. The sheath 102 may also be substantially flat because the fluid collection assembly 100 may not include relatively rigid rings or caps that exhibit a rigidity that is greater than the portions of the fluid impermeable barrier 108 thereabout since such rings and caps may inhibit the sheath 102 being substantially flat. It is noted that the sheath 102 is described as being substantially flat because at least one of the porous material 115 may cause a slight bulge to form in the sheath 102 depending on the thickness of the porous material 115, the fluid outlet 118 and/or conduit 130 may cause a bulge thereabout, or the base 104 may pull on portions of the sheath 102 thereabout. It is also noted that the sheath 102 may also be compliant and, as such, the sheath 102 may not be substantially flat during use since, during use, the sheath 102 may rest on a non-flat surface (e.g., may rest on the testicles, the perineum, and/or between the thighs) and the sheath 102 may conform to the surface of these shapes.


The ability of the sheath 102 to be substantially flat when the penis is not in the penis receiving area 128 and the sheath 102 is resting on a flat surface allows the fluid collection assembly 100 to be used with a buried and a non-buried penis. For example, when the fluid collection assembly 100 is being used with a buried penis, the penis does not extend into the penis receiving area 128 which causes the sheath 102 to lie relatively flat across the aperture 132 of the base 104. When the sheath 102 lies relatively flat across the aperture 132, the porous material 115 extends across the opening 116 and the aperature 132 and is in close proximity to the buried penis. As such, the porous material 115 prevents or inhibits pooling of bodily fluids discharged from the buried penis against the skin of the individual since the porous material 115 will receive and remove at least a significant portion of the bodily fluids that would otherwise pool against the skin of the individual. Thus, the skin of the individual remains dry thereby improving comfort of using the fluid collection assembly 100 and preventing skin degradation. However, unlike other conventional fluid collection assemblies that are configured to be used with buried penises, the fluid collection assembly 100 may still be used with a non-buried penis since the non-buried penis can still be received into the penis receiving area 128, even when the penis is fully erect. Additionally, the ability of the sheath 102 to be substantially flat allows the fluid collection assembly 100 to be used more discretely than if the sheath 102 was not substantially flat thereby avoiding possibly embarrassing scenarios.


When the sheath 102 is substantially flat, the porous material 115 occupies substantially all of the chamber 114 and the penis receiving area 128 is collapsed (shown as being non-collapsed in FIG. 1B for illustrative purposes to show the penis receiving area 128). In other words, the sheath 102 may not define an region that is constantly unoccupied by the porous material 115. When the porous material 115 occupies substantially all of the chamber 114, the bodily fluids discharged into the chamber 114 are unlikely to pool for significant periods of time since pooling of the bodily fluids may cause sanitation issues, cause an odor, and/or may cause the skin of the individual to remain in contact with the bodily fluids which may cause discomfort and skin degradation.


As previously discussed, the first panel 110, the second panel 112, and the porous material 115 may be selected to be relatively flexible. The first panel 110, the second panel 112, and the porous material 115 are relatively flexible when the first panel 110, the second panel 112, and the porous material 115, respectively, are unable to maintain their shape when unsupported. The flexibility of the first panel 110, the second panel 112, and the porous material 115 may allow the sheath 102 to be substantially flat, as discussed above. The flexibility of the first panel 110, the second panel 112, and the porous material 115 may also allow the sheath 102 to conform to the shape of the penis even when the size and shape of the penis changes (e.g., becomes erect) and to minimize any unoccupied spaces in the chamber 114 in which bodily fluids may pool.


As previously discussed, the fluid collection assembly 100 includes a base 104 that is configured to be attached to the sheath 102. For example, the base 104 is configured to be permanently attached to the sheath 102. The base 104 is configured to be permanently attached to the sheath 102 when, for example, when the fluid collection assembly 100 is provided with the base 104 permanently attached to the sheath 102 or the base 104 is provided without being permanently attached to the sheath 102 but is configured to be permanently attached to the sheath 102 at some point in the future. Permanently attached means that the sheath 102 cannot be detached from the base 104 without damaging at least one of the sheath 102 or the base 104, using a blade to separate the sheath 102 from the base 104, and/or using chemicals to dissolve the adhesive that attaches the sheath 102 from the base 104. The base 104 may be permanently attached to the sheath 102 using an adhesive, sewing, heat sealing, RF welding, or US welding. In an embodiment, the base 104 is configured to be reversibly attached to the sheath 102.


As previously discussed, the base 104 includes an aperture 132. The base 104 is permanently attached to the first end region 120 of the sheath 102 such that the aperture 132 is aligned with the opening 116.


The base 104 is sized, shaped, and made of a material to be coupled to the skin that surrounds the penis (e.g., mons pubis, thighs, testicles, and/or perineum) and have the penis disposed therethrough. For example, the base 104 may define an aperture 132 configured to have the penis positioned therethrough. In an example, the base 104 may exhibit the general shape or contours of the skin surface that the base 104 is configured to be coupled with. The base 104 may be flexible, thereby allowing the base 104 to conform to any shape of the skin surface and mitigate the base 104 pulling the on skin surface. The base 104 may extend laterally past the sheath 102 thereby increasing the surface area of the skin of the individual to which the fluid collection assembly 100 may be attached compared to a substantially similar fluid collection assembly 100 that did not include a base.



FIG. 1C is an enlarged cross-sectional schematic of a portion of the base 104, according to an embodiment. As illustrated, the base 104 may include a substrate 134. The substrate 134 includes a top surface 136 and a bottom surface 138. The top surface 136 is closer to the sheath 102 than the bottom surface 138 while the bottom surface 138 is, during use, closer to the skin of the individual than the top surface 136. In an embodiment, a portion of the top surface 136 may be attached to or configured to be attached to the sheath 102.


The substrate 134 may be formed from any suitable material. In an embodiment, the substrate 134 may be formed from fluid impermeable material(s), such as any of the fluid impermeable materials disclosed herein. In such an embodiment, the substrate 134 inhibits bodily fluids from leaking therethrough. In an embodiment, the substrate 134 is formed from a porous material, such as a porous material that is air-permeable and water impermeable (e.g., a hydrophobic porous material). In such an embodiment, the substrate 134 may allow air to flow therethrough thereby encouraging fluid flow through the fluid collection assembly 100 and preventing a suction force provided to the fluid collection assembly 100 from giving the patient a hickie. In an embodiment, the substrate 134 may be formed from a flexible material and/or may exhibit a relatively thin thickness (e.g., less than about 2 mm, less than about 1 mm, less than about 0.5 mm, or in ranges of about 0.25 mm to about 0.75 mm, about 0.5 mm to about 1 mm, about 0.75 mm to about 1.5 mm, or about 1 mm to about 2 mm). The flexibility and/or thickness of the substrate 134 may allow the substrate 134 to be shaped to conform to the shape of the region about the urethral opening (e.g., mons pubis, testicles, etc.) without pulling on the region about the urethral opening.


The base 104 also include a securement body 106. The securement body 106 includes a support 140 that is distinct from the substrate 134. At least a portion of the support 140 is attached to at least a portion of bottom surface 138 of the substrate 134. The support 140 may be attached to the substrate 134 using any suitable technique, such as with an adhesive, ultrasonic welding, etc. Generally, the attachment between the substrate 134 and the support 140 is greater than a maximum attachment between the securement body 106 and the skin of the patient such that detaching the base 104 from the patient is unlikely to detach the support 140 from the substrate 134. It is noted that the securement body 106 and the support 140 may be attached to components of the fluid collection assembly 100 other than or in addition to the base 104, as will be discussed in more detail below.


The support 140 may be formed from any suitable material. In an embodiment, the support 140 may be formed from fluid impermeable material(s), such as any of the fluid impermeable materials disclosed herein. In such an embodiment, the support 140 inhibits bodily fluids from leaking therethrough. In an embodiment, the support 140 is formed from a porous material, such as a porous material that is air-permeable and water impermeable (e.g., a hydrophobic porous material). In such an embodiment, the support 140 may allow air to flow therethrough thereby encouraging fluid flow through the fluid collection assembly 100 and preventing a suction force provided to the fluid collection assembly 100 from giving the patient a hickie. In an embodiment, the support 140 may be formed from a flexible material and/or may exhibit a relatively thin thickness (e.g., less than about 2 mm, less than about 1 mm, less than about 0.5 mm, or in ranges of about 0.25 mm to about 0.75 mm, about 0.5 mm to about 1 mm, about 0.75 mm to about 1.5 mm, or about 1 mm to about 2 mm). The flexibility and/or thickness of the support 140 may allow the support 140 to be shaped to conform to the shape of the region about the urethral opening (e.g., mons pubis, testicles, etc.) without pulling on the region about the urethral opening.


The securement body 106 includes a plurality of fibers 142 extending from support 140. The plurality of fibers 142 are configured to attach the base 104 to the region about the urethral opening. The plurality of fibers 142 exhibit a large surface area due to the relatively small lateral dimensions d (e.g., diameters) thereof, as discussed in more detail below. The large surface area of the fibers 142 cause the fibers 142 to exhibit sufficiently large Van der Waal forces with the region about the urethral opening (e.g., the skin and hair about the urethral opening) that the fibers 142 securely attach the base 104 to the region about the urethral opening. In some embodiments, the fibers 142 may attach the base 104 to the region about the urethral opening as strongly as some chemical adhesives (e.g., hydrogels) when certain forces are applied to the base 104. However, the fibers 142 remain part of the base 104 when the base 104 is detached from the region about the urethral opening unlike chemical adhesives which may leave a film attached to the region about the urethral opening. In an example, since the fibers 142 remain part of the base 104, at least the base 104 may be reused. In such an example, the base 104 may be detached from the region about the urethral opening to allow for examination of the urethral opening and the region about the urethral opening (e.g., regardless if the panels are transparent) and, after examination, the base 104 may be reattached to the region about the urethral opening. Additionally or alternatively, after detaching the base 104 from the region about the urethral opening, the base 104 and, optionally, the sheath 104 may be washed and reused with the same or a new patient. In an example, the fibers 142 may be able to attach the base 104 to the region about the urethral opening when the region about the urethral opening is wet, dry, shaved, or hairy.


The fibers 142 may be selected to exhibit an average lateral dimension d. As used herein, the average lateral dimension d may refer to the average lateral dimension of one fiber 142 at a single location, the average lateral dimension of one fiber 142 averaged along a length thereof, or the average lateral dimension averaged across at least some (e.g., all) of the fibers 142. The average lateral dimension d may be selected to be less than about 10 μm, less than about 8 μm, less than about 6 μm, less than about 5 μm, less than about 4 μm, less than about 3 μm, less than about 2.5 μm, less than about 2 μm, less than about 1.5 μm, less than about 1 μm, less than about 750 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, less than about 25 nm, less than about 10 nm, or in ranges of about 5 nm to about 25 nm, about 10 nm to about 50 nm, about 25 nm to about 75 nm, about 50 nm to about 100 nm, about 75 nm to about 150 nm, about 100 nm to about 200 nm, about 150 nm to about 300 nm, about 200 nm to about 400 nm, about 300 nm to about 500 nm, about 400 nm to about 600 nm, about 500 nm to about 750 nm, about 600 nm to about 1 μm, about 750 μm to about 1.5 μm, about 1 μm to about 2 μm, about 1.5 μm to about 3 μm, about 2 μm to about 4 μm, about 3 μm to about 5 μm, about 4 μm to about 7.5 μm, or about 5 μm to about 10 μm. The average lateral dimension d may be selected based on a number of factors.


In an example, the average lateral dimension d may be selected based on the desired adhesion between the securement body 106 and the region about the urethral opening. For instance, decreasing the average lateral dimension d increases the surface area of the fibers 142. The Vander der Waal forces between the fibers 142 and the region about the urethral opening increases as the surface area of the fibers 142 increase and the adhesion between the securement body 106 and the region about the urethral opening increases as the Vander de Waal forces increase. It is noted that the adhesion between the securement body 106 and the region about the urethral opening also depends on other factors, such as the number of fibers per unit of surface area of the support 140 and the length of the fibers 142.


In an example, the average lateral dimension d of the fibers 142 may be selected based on the material that forms the fibers 142. For instance, as previously discussed, the Vander der Waal forces between the fibers 142 and the region about the urethral opening depends on the surface area of the fibers 142 that are proximate to the region about the urethral opening. The surface area of the fibers 142 that are proximate to the region about the urethral opening may depend on the flexibility of the fibers 142. The flexibility of the fibers 142 depends inversely to the average lateral dimension d of the fibers 142 and inversely to the Young's modulus (i.e., modulus of elasticity) of the material that forms the fibers 142. As such, the average lateral dimension d may need to be increased as the Young's modulus of the material that forms the fibers 142 is decreased, and vice versa. In an embodiment, the fibers 142 are formed from a polymer, such as polyimide, polypropylene, polydimethylsiloxane, or any other suitable polymer. In such an embodiment, the average lateral dimension d of the fibers 142 may depend on the molecular weight of the polymer. In an embodiment, the fibers 142 are formed from carbon nanotubes. In such an embodiment, the fibers 142 may exhibit an average lateral dimension d that less than 100 nm, less than 50 nm, or more particularly less than 25 nm.


In an example, the average lateral dimension d of the fibers 142 may depend on the average length l of the fibers 142. For instance, increasing the average length l may increase the likelihood that the fibers 142 become tangled. Tangling the fibers 142 may prevent some of the fibers 142 from pressing against the region of the urethral opening that would press against the region about the urethral opening if not for the tangling. Thus, even though increasing the average length l generally increases the surface area of the fibers 142, increasing the average length l above a threshold value may cause the fibers 142 to become tangled and decrease the adhesion between the securement body 106 and the region about the urethral opening. The threshold value may be increased by increasing the average lateral dimension d of the fibers 142. Thus, increasing the average lateral dimension d allows the lengths of the fibers 142 to be increased without the accompanying issues of entanglement. It is noted that, as used herein, the average length l may refer to the length of a single fiber 142, the length averaged across some of the fibers 142, or the length averaged across all of the fibers 142.


In an embodiment, the average length l of the fibers 142 may be selected to be greater than about 500 nm, greater than about 750 nm, greater than about 1 μm, greater than about 2 μm, greater than about 3 μm, greater than about 5 μm, greater than about 7.5 μm, greater than about 10 μm, greater than about 15 μm, greater than about 25 μm, greater than about 50 μm, greater than about 75 μm, greater than about 100 μm, or in ranges of about 500 nm to about 1 μm, about 750 nm to about 1.5 μm, about 1 μm to about 2 μm, about 1.5 μm to about 3 μm, about 2 μm to about 5 μm, about 3 μm to about 7.5 μm, about 5 μm to about 10 μm, about 7.5 μm to about 15 μm, about 10 μm to about 25 μm, about 15 μm to about 50 μm, about 25 μm to about 75 μm, or about 50 μm to about 100 μm. As previously discussed, the average length l of the fibers 142 may be selected based on the average lateral dimension d and desired surface area of the fibers 142 that is proximate to the region about the urethral opening. The average length l of the fibers 142 may also be selected based on the material(s) that form the fibers 142 since increasing and decreasing the Young's modulus of the material(s) that form the fibers 142 increases and decreases, respectively, the entanglement threshold.


Generally, the average length l of the fibers 142 are greater than the average lateral dimension d. For example, the average length l of the fibers 142 may be selected to be greater than the average lateral dimension d by a factor that is at least about 5, at least about 10, at least about 20, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 300, at least about 500, or in ranges of about 5 to 20, about 20 to about 30, about 20 to about 30, about 30 to about 75, about 50 to about 100, about 75 to about 150, about 100 to about 200, about 150 to about 300, or about 200 to about 500.


The fibers 142 may extend from the support 140 at an average angle θ. The average angle θ is an oblique angle. The angle θ is the average smallest angle that may be measured from an outer surface 144 of the support 140 to a portion of the fibers 142 adjacent to the support 140 when no external force is pressing against the fibers 142. The average angle θ may be the angle θ measure between one, some, or all of the fibers 142. The angle θ may be about 1° to about 10°, about 5° to about 15°, about 10° to about 20°, about 15° to about 25°, about 20° to about 30°, about 25° to about 35°, about 30° to about 40°, about 35° to about 45°, about 40° to about 50°, about 45° to about 60°, about 55° to about 75°, or about 70° to about 89°. The average angle θ generally corresponds to the angle between the fibers 142 and the region about the urethral opening assuming the base 104 is sufficiently flexible that the base 104 generally corresponds to the region about the urethral opening. Decreasing the angle θ increases the surface area of the fibers 142 that are proximate to the region about the urethral opening which, in turn, increases the adhesion between the securement body 106 and the region about the urethral opening. Generally, decreasing the average angle θ to be less than about 45° and less than about 30° may allow the fibers 142 to be significantly better at resisting shear forces than if the average angle θ was greater than these values.


The average angle θ may be selected to facilitate attachment, detachment, and securement of the base 104 to the region about the urethral opening. In an example, referring to FIG. 1A, and the base 104 may include a first region 146 and a second region 148. The first region 146 is configured to be attached to the mons pubis while the second region 148 is configured to be attached around the shaft of the penis. The mons pubis exhibits a significantly larger surface area than the area around the shaft of the penis to which the base 104 may be attached. As such, the first region 146 may exhibit a larger surface area than the second region 148. In an embodiment, referring to FIG. 1C, the average angle θ is selected to be less than about 45° (e.g., less than about 30°) and such that at least most of the fibers 142 extend from the support 140 in a direction that generally extends from the second region 148 to the first region 146. In such an embodiment, during use, the base 104 may press into the region about the urethral opening when the patient is lying on the patient's backs such that significant adhesion is not necessary to maintain the base 104 attached to the region about the urethral opening. However, when the patient stands, the average angle θ may resist the shear forces caused by pulling the fluid collection assembly 100 downwards (e.g., towards the feet of the patient). In fact, pulling the fluid collection assembly 100 downwards may decrease the average angle θ thereby increasing adhesion of the base 104 to the region about the urethral opening. However, pulling the fluid collection assembly 100 upwards (e.g., towards the head) or perpendicular to the region about the urethral opening may decrease the average angle θ thereby decreasing adhesion between the securement body 106 and the region about the urethral opening. In other words, the securement body 106 may be more easily detached from the patient (e.g., detached less painfully) when the fluid collection assembly 100 is pulled upward or perpendicular from the region about the urethral opening.


It is noted that the average angle θ does not need to be selected such that the fibers 142 do not extend from the second region 148 to the first region 146. In an example, the average angle θ may be selected such that the fibers 142 extend from the first region 146 to the second region 148. In such an example, a large force pulling downward on the fluid collection assembly 100 may cause the securement body 106 to become detached from the patient which may be beneficial when the downward force is sufficient to cause patient pain if the securement body 106 did not become detached. In an example, the average angle θ may be selected such that the fibers 142 do not extend from the first region 146 to the second region 148 or from the second region 148 to the first region 146 (e.g., the fibers 142 extend in a sideways direction). In such an example, the securement body 106 may be used with a patient that remains mostly in-bed since the downward force applied to the fluid collection assembly 100 caused by standing is not likely to be a factor.


As discussed above, the average angle θ is relative to the outer surface 144 of the support 140. However, as will be discussed in more detail below, the fibers 142 may extend from at least one exterior surface of the fluid collection assembly 100 other than or in addition to the outer surface 144 of the support 140. For example, the fibers 142 may extend from the bottom surface 138 of the substrate 134 (as shown in FIGS. 1E and 1F) or the fluid impermeable barrier 108 (as discussed with regards to FIGS. 3A and 3B). As such, it is noted that the average angle θ is measure relative to the at least one exterior surface of the fluid collection assembly from which the fibers extend.


The securement body 106 may include at least 5,000 fibers per square centimeter of surface area of the outer surface 144 of the support 140 (“f/sc”), at least 10,000 f/sc, at least about 25,000 f/sc, at least about 50,000 f/sc, at least about 75,000 f/sc, at least about 100,000 f/sc, at least about 150,000 f/sc, at least about 200,000 f/sc, at least about 300,000 f/sc, at least about 500,000 f/sc, at least about 750,000 f/sc, at least about 1,000,000 f/sc, at least about 1,500,000 f/sc, at least about 2,500,000 f/sc, at least about 5,000,000 f/sc, at least about 10,000,000 f/sc, at least about 20,000,000 f/sc, or in ranges of about 10,000 f/sc to about 50,000 f/sc, about 25,000 f/sc to about 75,000 f/sc, about 50,000 f/sc to about 100,000 f/sc, about 75,000 f/sc to about 150,000 f/sc, about 100,000 f/sc to about 200,000 f/sc, about 150,000 f/sc to about 300,000 f/sc, about 200,000 f/sc to about 500,000 f/sc, about 300,000 f/sc to about 750,000 f/sc, about 500,000 f/sc to about 1,000,000 f/sc, about 750,000 f/sc to about 1,500,000 f/sc, about 1,000,000 f/sc to about 2,500,000 f/sc, about 1,500,000 f/sc to about 5,000,000 f/sc, about 2,500,000 f/sc to about 10,000,000 f/sc, or about 5,000,000 f/sc to about 20,000,000 f/sc. Increasing and decreasing number of fibers 142 per square centimeter of surface area of the outer surface 144 of the support 140 increases and decreases, respectively, the adhesion between the securement body 106 and the region about the urethral opening. As such, the number of fibers 142 per square centimeter of surface area of the outer surface 144 may be selected based on the desired adhesion, other factors that affect adhesion (e.g., average lateral dimension d, average length 1, etc.), and the maximum number of fibers 142 that may reasonably fit within the square centimeter.


In an embodiment, securement body 106 may include one or more branches 150 extending therefrom. The branches 150 may extend from or attached to a portion of the fibers 142 at or near the terminal end thereof. For illustrative purposes (i.e., to more clearly illustrated the fibers 142 and prevent clutter), only one of the fibers 142 are illustrated as having branches 150 extending therefrom. The branches 150 may increase the surface area of the fibers 142 which, in turn, increases the adhesion between the securement body 106 and the region about the urethral opening. The branches 150 exhibit an average diameter and an average length that is significantly less than the average lateral dimension d and the average length l of the fibers 142. For example, the average diameter and/or average length of the branches 150 may be less than the average lateral dimension d and/or average length l of the fibers 142, respectively, by at least about 2, at least about 5, at least about 10, at least about 15, at least about 20, at least about 30, at least about 40, at least about 50, or in ranges of about 2 to about 10, about 5 to about 15, about 10 to about 20, about 15 to about 30, about 20 to about 40, or about 30 to about 50. In an example, the average diameter of the branches 150 may exhibit be less than about less than about 2 μm, less than about 1.5 μm, less than about 1 μm, less than about 750 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, less than about 25 nm, less than about 10 nm, less than about 5 nm or in ranges of about 1 nm to about 10 nm, about 5 nm to about 25 nm, about 10 nm to about 50 nm, about 25 nm to about 75 nm, about 50 nm to about 100 nm, about 75 nm to about 150 nm, about 100 nm to about 200 nm, about 150 nm to about 300 nm, about 200 nm to about 400 nm, about 300 nm to about 500 nm, about 400 nm to about 600 nm, about 500 nm to about 750 nm, about 600 nm to about 1 μm, about 750 μm to about 1.5 μm, or about 1 μm to about 2 μm. In an example, the length of the branches 150 may be less than about 500 nm, less than about 750 nm, less than about 1 μm, less than about 2 μm, less than about 3 μm, less than about 5 μm, less than about 7.5 μm, less than about 10 μm, less than about 15 μm, less than about 25 μm, less than about 50 μm, less than about 75 μm, less than about 100 μm, or in ranges of about 500 nm to about 1 μm, about 750 nm to about 1.5 μm, about 1 μm to about 2 μm, about 1.5 μm to about 3 μm, about 2 μm to about 5 μm, about 3 μm to about 7.5 μm, about 5 μm to about 10 μm, about 7.5 μm to about 15 μm, about 10 μm to about 25 μm, or about 15 μm to about 50 μm. In an embodiment, one or more of the branches 150 may branch into a plurality of additional branches.


Referring to FIG. 1C, the fibers 142 are distinct from the support 140. As such, the fibers 142 may be formed on the support 140 or formed separately from the support 140 and attached to the support 140 after forming the fibers 142. In an example, the fibers 142 may be formed via an electro-spinning technique and attached to the support 140. In an example, the fibers 142 may be grown on the support 140, for instance, using a chemical vapor deposition (“CVD”) or physical vapor deposition (“PVD”) technique. In such an example, the support 140 may be masked prior to growing the fibers 142 on the support 140. The mask may be removed from the support 140 after growing the fibers 142 or the mask may remain. In an example, the fibers 142 may be formed using an overmolding and/or micromolding technique.


The base 104 may exhibit a different structure than the structure illustrated in FIG. 1C depending on the technique used to form the fibers 142. FIGS. 1D to 1F are cross-sectional schematics of different bases that may be used with the fluid collection assembly 100, according to different embodiments. Referring to FIG. 1D, the base 104d includes a substrate 134d that is the same or substantially similar to the substrate 134 of FIG. 1C. The base 104d also include a securement body 106d. The securement body 106d includes a support 140d and a plurality of fibers 142d. The support 140d and the fibers 142d may be the same or substantially similar to the support 140 and the fibers 142 of FIG. 1C, respectively, (e.g., formed from any of the support and/or fibers materials disclosed herein) except that the support 140d and the fibers 142d are integrally formed with each other. An example of forming the securement body 106d includes providing a piece of material. Portions of the material may be selectively removed therefrom to form the support 140d and the fibers 142d. The portion of the material may be selectively removed using a photolithography technique or any other suitable technique. It is noted that a mask may be formed on the portions of the material that form the fibers 142d to prevent the removal of such portions of the material. The masks may be removed after forming the fibers 142d.


Referring to FIG. 1E, the base 104e may include a substrate 134e and a securement body 106e attached to the substrate 134e. The securement body 106e include one or more fibers 142e that extend directly from and are distinct from the substrate 134e. In other words, at least a portion of the securement body 106e does not include a support. The fibers 142e may be formed directly on the substrate 134e in any of the same manners that the fibers 142 are formed on the support 140 of FIG. 1C. For example, preformed fibers (e.g., electro-spun fibers) may be directly attached to the substrate 134e or the fibers 142e may be grown on the substrate 134e (e.g., using CVD or PVD).


Referring to FIG. 1F, the base 104f may include a substrate 134f and a securement body 106f that are integrally formed together. For example, the securement body 106f may include a plurality of fibers 142f that are integrally formed with the substrate 134f. The base 104f may be formed by providing a piece of material and selectively removing portions of the material to form the fibers 142f. In an example, portions of the material may be removed via photolithography. In such an example, the material may be masked to prevent removal of portions of the material that form the fibers 142f. The mask may be removed after forming the fibers 142f.


Referring back to FIGS. 1A and 1B, it is noted that the securement bodies disclosed herein may be formed on at least a portion of the fluid impermeable barrier 108 instead of or in addition to the base 104. For example, the securement body formed on at least a portion of the fluid impermeable barrier 108 may include fibers attached to a support that is attached to the fluid impermeable barrier 108, integrally formed with the support that is attached to the fluid impermeable barrier 108, directly attached to the fluid impermeable barrier 108, or integrally formed with the fluid impermeable barrier 108.


As previously discussed, the fluid collection assembly 100 includes a conduit 130. The conduit 130 may be the same or substantially similar to any of the assembly tubes disclosed herein. An inlet of the conduit 130 may be located at or near the second end region 122 of the sheath 102 which is expected to be the gravimetrically low point of the chamber 114 when worn by a user. Locating the inlet of the conduit 130 at or near the second end region 122 of the sheath 102 enables the conduit 130 to receive more of the bodily fluids than if the inlet of the conduit 130 was located elsewhere and reduce the likelihood of pooling (e.g., pooling of the bodily fluids may cause microbe growth and foul odors). For instance, the bodily fluids in porous material 115 flow into the porous material 115 due to capillary forces. However, the bodily fluids may exhibit a preference to flow in the direction of gravity, especially when at least a portion of the porous material 115 is saturated with the bodily fluids. Accordingly, the inlet of the conduit 130 may be located in the fluid collection assembly 100 in a position expected to be the gravimetrically low point in the fluid collection assembly 100 when worn by a user.


In an example, the conduit 130 is configured to be at least insertable into the chamber 114, such as into the penis receiving area 128. In such an example, the conduit 130 may include one or more markers (not shown) on an exterior thereof that are located to facilitate insertion of the conduit 130 into the chamber 114. For example, the conduit 130 may include one or more markings thereon that are configured to prevent over or under insertion of the conduit 130. In another example, the conduit 130 may include one or more markings thereon that are configured to facilitate correct rotation of the conduit 130 relative to the chamber 114. The one or more markings may include a line, a dot, a sticker, or any other suitable marking.


The conduit 130 may include a flexible material such as plastic tubing (e.g., medical tubing). Such plastic tubing may include a thermoplastic elastomer, polyvinyl chloride, ethylene vinyl acetate, polytetrafluoroethylene, etc., tubing. In some examples, the conduit 130 may include silicon or latex. In some examples, the conduit 130 may include one or more portions that are resilient, such as to by having one or more of a diameter or wall thickness that allows the conduit 130 to be flexible.


As described in more detail below, the conduit 130 is configured to be coupled to, and at least partially extend between, one or more of the fluid storage container (not shown) and the vacuum source (not shown). In some examples, the vacuum source may be remotely located from the fluid collection assembly 100. In such examples, the conduit 130 may be fluidly connected to the fluid storage container, which may be disposed between the vacuum source and the fluid collection assembly 100.


During operation, a male using the fluid collection assembly 100 may discharge bodily fluids (e.g., urine) into the chamber 114. The bodily fluids may pool or otherwise be collected in the chamber 114. At least some of the bodily fluids may be pulled through the interior of the conduit 130 via the inlet. The fluid may be drawn out of the fluid collection assembly 100 via the vacuum/suction provided by the vacuum source. Further examples of male fluid collection assemblies are disclosed in U.S. Provisional Patent Application No. 63/067,542 filed on Aug. 19, 2020, the disclosure of which is incorporated herein, in its entirety, by this reference.


The securement body disclosed herein may be used with other male fluid collection assemblies. For example, FIG. 2 is a cross-sectional schematic of a fluid collection assembly 200, according to an embodiment. The fluid collection assembly 200 is a male fluid collection assembly configured to receive one or more bodily fluids from a male urethral opening. Except as otherwise disclosed herein, the fluid collection assembly 200 is the same or substantially similar to any of the fluid collection assemblies disclosed herein.


The fluid collection assembly 200 includes a sheath 202 and a base 204 and a sheath 202. The sheath 202 includes (e.g., may be formed from) a fluid impermeable barrier 208 that is sized and shaped to fit into the hollowed region of the base 204. For example, the sheath 202 may be generally tubular or cup-shaped, as shown. The generally tubular or cup-shaped fluid impermeable barrier 208 may at least partially define the outer surface 226 of the sheath 202. The fluid impermeable barrier 208 may be similar or identical to the fluid impermeable barrier 108 as disclosed herein, in one or more aspects. For example, the fluid impermeable barrier 208 may be constructed of any of the materials disclosed herein for the fluid impermeable barrier 108. The fluid impermeable barrier 208 at least partially defines the chamber 214. For example, the inner surface 224 of the fluid impermeable barrier 208 at least partially defines the perimeter of the chamber 214. The chamber 214 may be similar or identical to the chamber 114 in one or more aspects. For example, the chamber 214 may at least temporarily retain fluids therein. As shown, the fluid collection assembly 200 may include the porous material 215 therein. The porous material 215 may be similar or identical to the porous material 115 in one or more aspects. In an example, the porous material 215 may include one or more of a fluid permeable membrane 252 or a fluid permeable support 254. In an example, the porous material 215 may include any of the other porous material disclosed herein. The fluid impermeable barrier 208 may also define an opening 216 extending through the fluid impermeable barrier 208 that is configured to have a male urethra positioned therethrough.


The sheath 202 also includes at least a portion of the conduit 230 therein, such as at least partially disposed in the chamber 214. For example, the conduit 230 may extend from the sheath 202 at the second end region 222 at least partially towards a first end region 220 at least proximate to the aperture 232. The first end region 220 may be disposed near or on the skin around the male urethra (e.g., on the penis or pubic area therearound).


In some examples, the fluid impermeable barrier 208 may be constructed of a material and/or have a thickness that allows the sheath 202 to collapse when placed under vacuum, such as to remove air around a penis in the fluid collection assembly 200 during use. In such examples, the conduit 230 may extend only to or into the second end region 222 in the chamber 214 (e.g., not through to the area adjacent the opening 216). In such examples, urine may be collected and removed from the fluid collection assembly 200 at the first end region 220. It is noted that the porous material 215 may not collapse when the sheath 202 collapses thereby allowing bodily fluids to flow through the fluid collection assembly 200.


In an example, portions of the chamber 214 may be substantially empty due to the varying sizes and rigidity of the male penis. However, in some examples, the outermost regions of the chamber 214 (e.g., periphery of the interior regions of the sheath 202) may include porous material 215 (e.g., one or more of the fluid permeable membrane 252 and fluid permeable support 254). For example, the porous material 215 may be bonded to the inner surface 224 of the fluid impermeable barrier 208. The porous material 215 may be positioned (e.g., at the distal end of the chamber 214) to blunt a stream of urine from the male urethra thereby limiting splashing and/or to direct the bodily fluids to a selected region of the chamber 214. Since the chamber 214 is substantially empty (e.g., substantially all of the chamber 214 forms a reservoir), the fluids are likely to pool at a gravimetrically low point of the chamber 214. The gravimetrically low point of the chamber 214 may be at an intersection of the skin of an patient and the fluid collection assembly 200, a corner formed in the sheath 202, or another suitable location depending on the orientation of the patient.


The porous material 215 may include any of the porous material(s) disclosed herein, In an example, as previously discussed, the porous material 215 may include one or more of the fluid permeable membrane 252 or the fluid permeable support 254. One or more of the fluid permeable membrane 252 or the fluid permeable support 254 may be disposed between the fluid impermeable barrier 208 and a penis inserted into the chamber 214. The fluid permeable membrane 252 may be positioned between the fluid impermeable barrier 208 and a penis inserted into the chamber 214, such as between the fluid permeable support 254 and penis of a patient as shown. The fluid permeable support 254 may be positioned between the fluid permeable membrane 252 and the fluid impermeable barrier 208. The inner surface 224, optionally including the end of the chamber 214 substantially opposite the opening 216, may be covered with one or both the fluid permeable membrane 252 or the fluid permeable support 254. The fluid permeable support 254 or the fluid permeable membrane 252 may be affixed (e.g., adhered) to the fluid impermeable barrier 208. The fluid permeable support 254 or the fluid permeable membrane 252 may be affixed to each other. In some examples, the porous material 215 only includes the fluid permeable membrane 252 or the fluid permeable support 254.


The base 204 is sized, shaped, and made of a material to be coupled to skin that surrounds the male urethra and have the male urethra positioned therethrough. For example, the base 204 may include an substrate 234 that defines an aperture 232 in the base 204. The substrate 234 is sized and shaped to be positioned around the male urethra (e.g., positioned around and/or over the penis) and the aperture 232 may be configured to have the male urethra positioned therethrough. The substrate 234 may also be sized, shaped, made of a material, or otherwise configured to be coupled (e.g., adhesively attached, such as with a hydrogel adhesive) to the skin around the male urethra (e.g., around the penis). In an example, the substrate 234 may exhibit the general shape or contours of the skin surface that the substrate 234 is selected to be coupled with. The substrate 234 may be flexible thereby allowing the substrate 234 to conform to any shape of the skin surface. The base 204 may include a longitudinally extending flange 255 extending from the substrate 234 and a laterally extending flange 257 extending inwardly from the longitudinal extending flange 255. The longitudinally extending flange 255 and the laterally extending flange 257 define a hollowed region that is configured to receive (e.g., seal against) the sheath 202.


The base 204 also includes at least one securement body 206. For example, the securement body 206 may be attached to at least a portion of a bottom surface 238 of the substrate 234. The securement body 206 may be the same or substantially similar to any of the securement body disclosed herein. For example, the securement body 206 includes a plurality of fibers (not shown) that are configured to be attach the base 204 to a region about the urethral opening. The fibers may be attached to a support that is attached to the bottom surface 238 of the substrate 234 (as shown in FIG. 1C), integrally formed with the support (as shown in FIG. 1D), directly attached to the substrate 234 (as shown in FIG. 1E), or integrally formed with the substrate 234 (as shown in FIG. 1F).


In some examples, the fluid collection assembly 200 includes a cap 256 at a second end region 222. The cap 256 defines an interior channel through which the fluids may be removed from the fluid collection assembly 200. The interior channel is in fluid communication with the chamber 214. The cap 256 may be disposed over at least a portion of the second end region 222 of one or more of the fluid impermeable barrier 208 or the porous material 215. The cap 256 may be made of a polymer, rubber, or any other fluid impermeable material. The cap 256 may be attached to one or more of the fluid impermeable barrier 208, the porous material 215, or the conduit 130. The cap 256 may cover at least a portion of the second end region 222 of the fluid collection assembly 200. The cap 256 may laterally extend a distance from the sheath 202. The cap 256 defines a fluid outlet 218 that is sized and configured to receive and fluidly seal against the conduit 230, such as within the interior channel. The conduit 230 may extend a distance within or through the cap 256, such as to the porous material 215, through the porous material 215, or to a point set-off from the porous material 215. In the latter example, the interior channel of the cap 256 may define a reservoir 258 therein. In some examples (not shown), the cap 256 may be omitted.


The reservoir 258 is an unoccupied portion of fluid collection assembly 200 such as in the cap 256 and is void of other material. In some examples, the reservoir 258 is defined at least partially by the porous material 215 and the cap 256. During use, the fluids that are in the chamber 214 may flow through the porous material 215 to the reservoir 258. The reservoir 258 may store at least some of the fluids therein and/or position the fluids for removal by the conduit 230. In some examples, at least a portion of the porous material 215 may extend continuously between at least a portion of the opening of the interior channel and chamber 214 to wick any fluid from the opening directly to the reservoir 258.


The base 204, the sheath 202, the cap 256, and the conduit 230 may be attached together using any suitable method. For example, at least two of the base 204, the sheath 202, the cap 256, or the conduit 230 may be attached together using at least one of an interference fit, an adhesive, stitching, welding (e.g., ultrasonic welding), tape, any other suitable method, or combinations thereof.


In some examples (not shown), the fluid collection assembly 200 may have a one piece design, with one or more of the sheath 202, the base 204, and the cap 256 being a single, integrally formed piece.


Further examples of male fluid collection assemblies that may be used here are disclosed in U.S. patent application Ser. No. 16/433,773 filed on Jun. 6, 2019, the disclosure of which is incorporated herein, in its entirety, by this reference.


The securement body disclosed herein may be used with a female fluid collection assembly. FIG. 3A is an isometric view of a fluid collection assembly 300, according to an embodiment. FIG. 3B is a cross-sectional schematic of the fluid collection assembly 300 taken along plane 3B-3B shown in FIG. 3A, according to an embodiment. The fluid collection assembly 300 is a female fluid collection assembly that is configured to be disposed adjacent to a female urethral opening. Except as otherwise disclosed herein, the fluid collection assembly 300 is the same or substantially similar to any of the fluid collection assemblies disclosed herein. The fluid collection assembly 300 includes a fluid impermeable barrier 308, at least one porous material 315 disposed in a chamber 314 defined by the fluid impermeable barrier 308, at least one securement body 306, and an optional conduit 330 at least partially disposed within the chamber 314.


The fluid impermeable barrier 308 at least partially defines a chamber 314 (e.g., interior region) and an opening 316. For example, the interior surface(s) 324 of the fluid impermeable barrier 308 at least partially defines the chamber 314 within the fluid collection assembly 300. The fluid impermeable barrier 308 temporarily stores the bodily fluids in the chamber 314. The fluid impermeable barrier 308 may be formed of any suitable fluid impermeable material(s), such as any of the fluid impermeable materials disclosed herein. As such, the fluid impermeable barrier 308 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 308. In an example, the fluid impermeable barrier 308 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 308 may be formed of a hydrophobic material that defines a plurality of pores. At least one or more portions of at least an outer surface 326 of the fluid impermeable barrier 308 may be formed from a soft and/or smooth material, thereby reducing chaffing.


In some examples, the fluid impermeable barrier 308 may be tubular (ignoring the opening 316), such as substantially cylindrical (as shown), oblong, prismatic, or flattened tubes. During use, the outer surface 326 of the fluid impermeable barrier 308 may contact the patient. The fluid impermeable barrier 308 may be sized and shaped to fit in the gluteal cleft between the legs of a female user.


The opening 316 provides an ingress route for fluids to enter the chamber 314. The opening 316 may be defined by the fluid impermeable barrier 308 such as by an inner edge of the fluid impermeable barrier 308. For example, the opening 316 is formed in and extends through the fluid impermeable barrier 308, from the outer surface 326 to the inner surface 324, thereby enabling bodily fluids to enter the chamber 314 from outside of the fluid collection assembly 300. The opening 316 may be an elongated hole in the fluid impermeable barrier 308. For example, the opening 316 may be defined as a cut-out in the fluid impermeable barrier 308. The opening 316 may be located and shaped to be positioned adjacent to a female urethra.


The fluid collection assembly 300 may be positioned proximate to the female urethral opening and the bodily fluids may enter the chamber 314 of the fluid collection assembly 300 via the opening 316. The fluid collection assembly 300 is configured to receive the bodily fluids into the chamber 314 via the opening 316. When in use, the opening 316 may have an elongated shape that extends from a first location below the urethral opening (e.g., at or near the anus or the vaginal opening) to a second location above the urethral opening (e.g., at or near the top of the vaginal opening or the pubic hair).


The opening 316 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the bodily fluids along a path that corresponds to the elongated shape of the opening 316 (e.g., longitudinally extending opening). The opening 316 in the fluid impermeable barrier 308 may exhibit a length that is measured along the longitudinal axis of the fluid collection assembly 300 that may be at least about 20% of the length of the fluid collection assembly 300, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 95% of the length of the fluid collection assembly 300.


The opening 316 in the fluid impermeable barrier 308 may exhibit a width that is measured transverse to the longitudinal axis of the fluid collection assembly 300 that may be at least about 30% of the circumference of the fluid collection assembly 300, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 300% of the circumference of the fluid collection assembly 300. The opening 316 may exhibit a width that is greater than 50% of the circumference of the fluid collection assembly 300 since the vacuum (e.g., suction) through the conduit 330 pulls the fluid through the porous material 315 and into the conduit 330. In some examples, the opening 316 may be vertically oriented (e.g., having a major axis parallel to the longitudinal axis of the fluid collection assembly 300). In some examples (not shown), the opening 316 may be horizontally oriented (e.g., having a major axis perpendicular to the longitudinal axis of the fluid collection assembly 300). In an example, the fluid impermeable barrier 308 may be configured to be attached to the patient, such as adhesively attached (e.g., with a hydrogel adhesive) to the patient. According to an example, a suitable adhesive is a hydrogel layer.


In some examples, the fluid impermeable barrier 308 may define an fluid outlet 318 sized to receive the conduit 330. The at least one conduit 330 may be disposed in the chamber 314 via the fluid outlet 318. The fluid outlet 318 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 330 or the at least one tube thereby substantially preventing the bodily fluids from escaping the chamber 314.


The fluid impermeable barrier 308 may include markings thereon, such as one or more markings to aid a user in aligning the fluid collection assembly 300 on the patient. For example, a line on the fluid impermeable barrier 308 (e.g., opposite the opening 316) may allow a healthcare professional to align the opening 316 over the urethra of the patient. In examples, the markings may include one or more of alignment guide or an orientation indicator, such as a stripe or hashes. Such markings may be positioned to align the fluid collection assembly 300 to one or more anatomical features such as a pubic bone, etc.


The fluid collection assembly 300 includes porous material 315 disposed in the chamber 314. The porous material 315 may cover at least a portion (e.g., all) of the opening 316. The porous material 315 is exposed to the environment outside of the chamber 314 through the opening 316. In an embodiment, the porous material 315 may be configured to wick any bodily fluids away from the opening 316, thereby preventing the bodily fluids from escaping the chamber 314. In an embodiment, the porous material 315 may include at least one absorbent or adsorbent material.


The porous material 315 may include any of the porous material disclosed herein. For example, the porous material 315 may include a fluid permeable membrane 352 and a fluid permeable support 354 disposed in the chamber 314. The fluid permeable membrane 352 may cover at least a portion (e.g., all) of the opening 316. The fluid permeable membrane 352 may be composed to wick the bodily fluids away from the opening 316, thereby preventing the bodily fluids from escaping the chamber 314. The fluid permeable membrane 352 may include any of the fluid permeable membrane materials disclosed herein.


The fluid permeable support 354 is configured to support the fluid permeable membrane 352 since the fluid permeable membrane 352 may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support 354 may be positioned such that the fluid permeable membrane 352 is disposed between the fluid permeable support 354 and the fluid impermeable barrier 308. As such, the fluid permeable support 354 may support and maintain the position of the fluid permeable membrane 352. The fluid permeable support 354 may include any material that may wick the bodily fluids, such as any of the fluid permeable membrane materials or fluid permeable support materials disclosed herein. For example, the fluid permeable membrane material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 352 when used as the fluid permeable support 354. The fluid permeable support 354 may be formed from any fluid permeable material that is less deformable than the fluid permeable membrane 352.


In some examples, the fluid permeable membrane 352 may be optional. For example, the porous material 315 may include only the fluid permeable support 354. In some examples, the fluid permeable support 354 may be optionally omitted from the fluid collection assembly 300. For example, the porous material 315 may only include the fluid permeable membrane 352.


The fluid permeable support 354 may have a greater ability to wick the bodily fluids than the fluid permeable membrane 352, such as to move the bodily fluids inwardly from the outer surface of the fluid collection assembly 300. In some examples, the porous ability of the fluid permeable support 354 and the fluid permeable membrane 352 may be substantially the same.


The fluid permeable membrane 352 and the fluid permeable support 354 may at least substantially completely fill the portions of the chamber 314 that are not occupied by the conduit 330. In some examples, the fluid permeable membrane 352 and the fluid permeable support 354 may not substantially completely fill the portions of the chamber 314 that are not occupied by the conduit 330. In such an example, the fluid collection assembly 300 includes the reservoir 358 disposed in the chamber 314.


The reservoir 358 is a substantially unoccupied portion of the chamber 314. The reservoir 358 may be defined between the fluid impermeable barrier 308 and one or both of the fluid permeable membrane 352 and fluid permeable support 354. The bodily fluids that are in the chamber 314 may flow through the porous material 315 to the reservoir 358. The fluid impermeable barrier 308 may retain the bodily fluids in the reservoir 358. While depicted in the first end region 320, the reservoir 358 may be located in any portion of the chamber 314 such as the second end region 322. The reservoir 358 may be located in a portion of the chamber 314 that is designed to be located in a gravimetrically low point of the fluid collection assembly when the fluid collection assembly is worn.


In some examples (not shown), the fluid collection assembly 300 may include multiple reservoirs, such as a first reservoir that is located at the portion of the chamber 314 closest to the inlet of the conduit 330 (e.g., first end region 320) and a second reservoir that is located at the portion of the of the chamber 314 that is at or near second end region 322). In another example, the fluid permeable support 354 is spaced from at least a portion of the conduit 330, and the reservoir 358 may be the space between the fluid permeable support 354 and the conduit 330.


The conduit 330 may be at least partially disposed in the chamber 314. The conduit 330 may be used to remove the bodily fluids from the chamber 314. The conduit 330 (e.g., a tube) includes an inlet of the conduit 330 and an outlet 312 positioned downstream from the inlet of the conduit 330. The outlet 312 may be operably coupled to a suction source, such as a vacuum pump for withdrawing fluid from the chamber 314 through the conduit 330. For example, the conduit 330 may extend into the fluid impermeable barrier 308 from the second end region 322 and may extend to the first end region 320 to a point proximate to the reservoir 358 therein such that the inlet of the conduit 330 is in fluid communication with the reservoir 358. The conduit 330 fluidly couples the chamber 314 with the fluid storage container (not shown) or the vacuum source (not shown).


The conduit 330 may extend through a bore in the fluid permeable membrane 352 and/or fluid permeable support 354, such as into the reservoir 358. For example, the inlet of the conduit 330 may be extend into or be positioned in the reservoir 358. In the illustrated embodiment, the conduit 330 is at least partially disposed in the reservoir 358. In some examples (not shown), the conduit 330 may enter the chamber 314 in the distal end region and the inlet of the conduit 330 of the conduit 330 may be disposed in the distal end region (e.g., in the reservoir 358). The bodily fluids collected in the fluid collection assembly 300 may be removed from the chamber 314 via the conduit 330.


In some examples, the inlet of the conduit 330 may not extend into the reservoir 358. In such examples, the inlet of the conduit 330 may be disposed within the porous material 315 (fluid permeable membrane 352 and/or fluid permeable support 354) or at a terminal end thereof. For example, an end of the conduit 330 may be coextensive with or recessed within the fluid permeable membrane 352 and/or fluid permeable support 354.


During use, the first end region 320 may be the gravimetrically low point of the chamber 314. As such, locating the inlet of the conduit 330 at or near a location expected to be the gravimetrically low point of the chamber 314 when worn by a patient enables the conduit 330 to receive more of the bodily fluids than if inlet of the conduit 330 was located elsewhere and reduce the likelihood of pooling (e.g., pooling of the bodily fluids may cause microbe growth and foul odors). For instance, as previously discussed, the bodily fluids in the fluid permeable membrane 352 and the fluid permeable support 354 may flow in any direction due to capillary forces. However, the bodily fluids may exhibit a preference to flow in the direction of gravity, especially when at least a portion of the fluid permeable membrane 352 and/or the fluid permeable support 354 is saturated with the bodily fluids. Accordingly, one or more of the inlet of the conduit 330 or the reservoir 358 may be located in the fluid collection assembly 300 in a position expected to be the gravimetrically low point in the fluid collection assembly 300 when worn by a patient, such as the first end region 320.


As previously discussed, the fluid collection assembly 300 may include at least one securement body 306. The securement body 306 may be configured to be attached to the skin of the patient, such as at least one of the thighs or the region about the urethral opening. As such, the securement body 206 may be attached to or formed on at least a portion of an outer surface 326 of the fluid impermeable barrier 308 that, during use, may contact the skin of the patient. The securement body 306 may be the same or substantially similar to any of the securement body disclosed herein. As such, the securement body 306 includes a plurality of fibers that are configured to be attach the securement body to the skin of a patient.


In an embodiment, the securement body 306 is distinct from the fluid impermeable barrier 308. In such an embodiment, the securement body 306 may include at least one of a plurality of fibers attached to or integrally formed with a support, similar to what is shown in FIGS. 1C and 1D, respectively. In such an embodiment, the support may be attached to the fluid impermeable barrier 308 using any suitable technique, such as with a chemical adhesive, a dry adhesive, etc. in an embodiment, the securement body 306 may include a plurality of fibers at least one of attached directly to the fluid impermeable barrier 308 or integrally formed with the fluid impermeable barrier 308, similar to what is shown in FIGS. 1E and 1F, respectively.


Other embodiments of fluid impermeable barriers, fluid permeable membranes, fluid permeable supports, chambers, and their shapes and configurations are disclosed in U.S. Pat. No. 10,973,678 filed on Jun. 2, 2017; U.S. Pat. No. 10,390,989 filed on Sep. 8, 2016; and U.S. Pat. No. 10,226,376 filed on Jun. 3, 2017, the disclosure of each of which is incorporated herein, in its entirety, by this reference.


The securement body illustrated in FIGS. 1A-3B include a plurality of fibers. However, the securement body may include one or more additional types of securement bodies, such at least one friction material, instead of or in addition to the securement bodies illustrated in FIGS. 1A-3B. For example, FIG. 4A is an isometric view of a fluid collection assembly 400 that includes at least one friction material 461, according to an embodiment. FIG. 4B is a cross-sectional schematic of the fluid collection assembly 400 taken along plane 4B-4B shown in FIG. 4A, according to an embodiment. The fluid collection assembly 400 is an example of a female fluid collection assembly. As such, except as otherwise disclosed herein, the fluid collection assembly 400 may be the same or substantially similar to the fluid collection assembly 300 shown in FIGS. 3A and 3B. For example, the fluid collection assembly 400 may include a fluid impermeable barrier 408 that defines a chamber 414, at least one opening 416, and a fluid outlet 418. The fluid collection assembly 400 may include at least one porous material 415 disposed in the chamber 414 and an optional conduit 430. Except as otherwise disclosed herein, the fluid impermeable barrier 408, the porous material 415, and the conduit 430 may be the same or substantially similar to any of the fluid impermeable barriers, porous materials, and conduits, respectively, disclosed herein.


The porous material 415 includes a contact surface 460 that is configured to contact the patient during use. The contact surface 460 may include the portion of the porous material 415 that extends across the opening 416.


The fluid collection 400 includes at least one securement body 406. The securement body 406 includes at least one friction material 461 disposed on at least a portion of the contact surface 460. The contact surface 460 exhibits a first coefficient of friction and the friction material 461 exhibits a second coefficient of friction that is greater than the first coefficient of friction. As such, the friction material 461 better prevents movement of the fluid collection assembly 400 when the opening is adjacent to the region about the urethral opening of the patient than if the fluid collection assembly 400 did not include the friction material 461. In is noted that, as used herein, the coefficient of friction refers to the coefficient of static friction of the material (e.g., the contact surface 460 or the friction material 461) against the against the skin of the patient when the skin is at least one of dry or moist.


The friction material 461 includes a material disposed on the contact surface 460 of the porous material 415. The material of the friction material 461 is different than the material that forms the porous material 415 which, at least in part, causes the friction material 461 to exhibit a coefficient of friction that is greater than the contact surface 460. In an example, the friction material 461 includes at least one elastomer, such as at least one of silicone, nitrile, rubber, neoprene, or another elastomer.


The friction material 461 may be disposed on the contact surface 460 using any suitable technique. In an example, the friction material 461 may include an adhesive on the surface of the friction material 461 that contacts the contact surface 460. In an example, the surface of the friction material 461 that contacts the contact surface 460 may be partially melted and the friction material 461 may be pressed into the contact surface 460. At least some of the melted portions of the friction material 461 may flow into and at least partially occupy some of the pores of the porous material 415 thereby attaching the friction material 461 to the porous material 415. In an example, the friction material 461 may be applied to the contact surface 460 while in a melted (e.g., liquid) state. Some of the melted friction material 461 may flow into and at least partially occupy some of the pores of the porous material 415 thereby attaching the friction material 461 to the porous material 415.


As previously discussed, the friction material 461 is disposed on the contact surface 460 of the porous material 415. As such, the friction material 461 may block portions of the porous material 415 that extend across the opening 416. In some embodiments, blocking portions of the porous material 415 that extend across the opening 416 may at least one of limit the amount of bodily fluids that may enter the chamber (not shown) or cause the bodily fluids to splash, either or which may cause bodily fluids to leak or otherwise inhibit the functionality of the fluid collection assembly 400. However, the friction material's 461 the ability to better maintain the position of the fluid collection assembly 400 against the region about the urethral opening still decreases the likelihood that the bodily fluids leak even though the friction material 461 may obstruct portions of the porous material 415 and cause splashing.


In an embodiment, the friction material 461 may define one or more passageways 462 (e.g., pores, voids, etc.) extending therethrough. The passageways 462 allow the bodily fluids to flow through the friction material 461 to the contact surface 460 of the porous material 415 and decrease splashing of the bodily fluids. Thus, the passageways 462 may further prevent bodily fluids from leaking from the fluid collection assembly 400. The passageways 462 may be formed using any suitable technique. In an example, the friction material 461 may be applied to the contact surface 460 in a manner that causes peaks and valleys to form and at least some of the valleys form the passageways 462. In an example, the friction material 461 may include one or more cutouts formed therein either before or after applying the friction material 461 to the contact surface 460. The cutouts may form the passageways 462. In an example, the friction material 461 may include a plurality of pores (e.g., interconnected pores) that form the passageways 462.


The friction material 461 illustrated in FIGS. 4A and 4B are in the form of dots. The friction material 461 are in the form of dots when at least some of the friction material 461 are completely laterally surrounded by the porous material 415. Optionally, some of the friction material 461 may be on the boundary between the fluid impermeable barrier 408 and the contact surface 460 and such friction material 461 are collectively completely laterally surrounded by the porous material 415 and the fluid impermeable barrier 408. Forming the friction material 461 as dots may allow for selective placement of the friction material 461, such as to avoid the urethral opening or increase the likelihood that the friction material 461 contacts skin. Further, forming the friction material 461 as dots may decrease the surface area of the contact surface 460 that the friction material 461 covers thereby decreasing the likelihood that the friction material 461 obstructs fluid flow or causes splashing.


The friction material 461 does not have to be arranged on the porous material 415 in the form of dots. For example, FIGS. 4C-4E are isometric views of different fluid collection assemblies that include the friction material disposed therein in different arrangements, according to different embodiments. Except as otherwise disclosed herein, the fluid collection assemblies illustrated in FIGS. 4C-4E are the same or substantially similar to any of the fluid collection assemblies disclosed herein.


Referring to FIG. 4C, the fluid collection assembly 400c includes a porous material 415c extending across at least one opening 416c and at least one securement body 406c. The securement body 406c includes at least one friction material 461d disposed on the porous material 415c. The friction material 461 is arranged as one or more longitudinally extending strips that extend generally parallel to a longitudinal axis of the fluid collection assembly 400c. The strips are more likely to contact anatomical features that extend obliquely or perpendicularly relative to a longitudinal axis of the of the fluid collection assembly 400c, such as the clitoral head, the mons pubis, and the perineum. The strips may also contact a greater percentage of anatomical features that generally extend parallel to the longitudinal axis of the fluid collection assembly 400c, such as the labia folds, if correctly positioned (e.g., the space between the strips are not spaced directly over the labia folds).


Referring to FIG. 4D, the fluid collection assembly 400d includes a porous material 415d extending across at least one opening 416d and at least one securement body 406d. The securement body 406d includes at least one friction material 461d disposed on the porous material 415d. The friction material 461d is arranged as one or more longitudinally extending strips that extend generally perpendicular to a longitudinal axis of the fluid collection assembly 400c. The strips are more likely to contact anatomical features that extend obliquely or parallel to a longitudinal axis of the of the fluid collection assembly 400c, such as the labia folds. For example, the strips illustrated in FIG. 4D are more likely to contact the labia folds than the strips illustrated in FIG. 4C regardless of the position of the fluid collection assemblies thereof. However, the strip illustrated in FIG. 4C may contact a greater percentage of the labia folds if the strips are disposed directly over the labia folds than the strips illustrated in FIG. 4D.


Referring to FIG. 4E, the fluid collection assembly 400e includes a porous material 415e extending across at least one opening 416e and at least one securement body 406e. The securement body 406e includes at least one friction material 461e disposed on the porous material 415e. The friction material 461e may be disposed on the porous material 415e to cover substantially all of the porous material. As such, the friction material 461e is more likely to contact skin and to contact a greater quantity of skin that the friction material illustrated in FIGS. 4A-4D. However, the friction material 461e must define one or more passageways 462e therethrough to allow the bodily fluids to flow into the chamber thereof (not shown).


It is noted that the arrangement of the friction material illustrated in FIGS. 4A-4E are provided for illustrative purposes only and that the friction material disclosed herein may exhibit different arrangements. In an example, the friction material may be arranged in strips that extend obliquely relatively to the longitudinal axis of the fluid collection assembly. In an example, the friction material may be arranged in the form of one or more dashed lines. In an example, the friction material may be arranged in a curved line. In an example, the friction material may be arranged in a combination of any of the arrangements disclosed herein (e.g., a checkered arrangement that includes a plurality of strips that extend parallel to and perpendicular to a longitudinal axis of the fluid collection assembly).


The friction materials disclosed above include the friction materials disposed on the porous material of female fluid collection assemblies. However, it is noted that the friction materials disclosed herein may be disposed on the porous materials of any of the male fluid collection assemblies disclose herein. Such friction materials may help maintain the penis in the chambers of such male fluid collection assemblies when the penis would otherwise become buried thereby preventing or minimizing pooling of bodily fluids caused by buried penises. The arrangement of the friction material on the porous materials of the male fluid collection assemblies may be the same or substantially similar to the arrangement of any of the friction material disclosed above with regards to the female fluid collection assemblies.


The fluid collection assemblies disclosed herein may include securement body instead of or in addition to the fibers and the friction materials disclosed above. For example, FIG. 5A is a cross-sectional schematic of a portion of a fluid collection assembly 500a, according to an embodiment. The fluid collection assembly 500a includes a base layer 564a. The base layer 564a may be, for example, a fluid impermeable layer, porous material, or a substrate of a base. The base layer 564a includes a top surface 566a and a bottom surface 568a. The bottom surface 568a is configured to be closer to a patient (e.g., adjacent to the skin of the patient) than the top surface 566a during use.


The fluid collection assembly 500a includes at least one securement body 506a. The securement body 506a include one or more suction cups 570a directly attached to or integrally formed with the base layer 564a. In particular, the suction cups 570a extend from the bottom surface 568a of the base layer 564a. The suction cups 570a are formed from a flexible material that is impermeable to air, such as nitrile, neoprene, polyurethane, silicone, rubber, vinyl, any other suitable polymer, or combinations thereof. The suction cups 570a may exhibit any concave shape. For example, the suction cups 570a may exhibit a conical or other cup-like shape having, for example, a circular or oblong opening.


The suction cups 570a may exhibit a maximum lateral dimension D (e.g., diameter). The maximum lateral dimension D of the suction cups 570a may be selected to be about 1 mm to about 3 mm, about 2 mm to about 4 mm, about 3 mm to about 5 mm, about 4 mm to about 6 mm, about 5 mm to about 7 mm, about 6 mm to about 8 mm, about 7 mm to about 9 mm, about 8 mm to about 1 cm, about 9 mm to about 1.2 cm, about 1 cm to about 1.4 cm, about 1.2 cm to about 1.6 cm, about 1.4 cm to about 1.8 cm, about 1.6 cm to about 2 cm, about 1.8 cm to about 2.25 cm, about 2 cm to about 2.5 cm, about 2.25 cm to about 2.75 cm, about 2.5 cm to about 3 cm, about 2.75 cm to about 3.5 cm, or about 3 cm to about 4 cm. The maximum lateral dimension D of the suction cups 570a may be selected based on a number of factors. Generally, the maximum lateral dimension D may be selected based on two competing factors, namely increasing the force required to detach the suction cups 570a and minimizing hickies and general discomfort caused by the suction cups 570a. For example, generally increasing the lateral dimension D may increase the force required to detach the suction cups 570a but also increases the likelihood of hickies and/or patient discomfort, especially if the fluid collection assembly 500a is used for a prolonged period of time. However, decreasing the maximum lateral dimension D may allow the fluid collection assembly 500a to include more suction cups 570a which may at least partially offset the decrease force required to detach the suction cups 570a.



FIG. 5B is a cross-sectional schematic of a portion of a fluid collection assembly 500b, according to an embodiment. Except as otherwise disclosed herein, the fluid collection assembly 500b is the same or substantially similar to the fluid collection assembly 500a. For example, the fluid collection assembly 500b may include a base layer 564b and at least one securement body 506b. However, the securement body 506b may include a support 540b and a plurality of suction cups 570b extending from the support 540b. The support 540b may the the same or substantially similar to the support 140 illustrated in FIG. 1C. The support 540b may facilitate manufacture of the base layer 564b. For example, the base layer 564b may be manufactured using traditional methods (e.g., extrusion, tape casting, etc.) instead of other techniques that are required to form the base layer 564b with the suction cups 570b directly disposed therein.



FIG. 6 is a block diagram of a system 672 for fluid collection, according to an embodiment. The system 672 includes a fluid collection assembly 600, a fluid storage container 674, and a vacuum source 676. The fluid collection assembly 600, the fluid storage container 674, and the vacuum source 676 may be fluidly coupled to each other via one or more conduits 630. For example, fluid collection assembly 600 may be operably coupled to one or more of the fluid storage container 674 or the vacuum source 676 via the conduit 630. Bodily fluids (e.g., urine or other bodily fluids) collected in the fluid collection assembly 600 may be removed from the fluid collection assembly 600 via the conduit 630 which protrudes into the fluid collection assembly 600. For example, an inlet of the conduit 630 may extend into the fluid collection assembly 600, such as to a reservoir therein. The outlet of the conduit 630 may extend into the fluid storage container 674 or the vacuum source 676. Suction force may be introduced into the chamber of the fluid collection assembly 600 via the inlet of the conduit 630 responsive to suction (e.g., vacuum) force applied at the outlet of the conduit 630.


The suction force may be applied to the outlet of the conduit 630 by the vacuum source 676 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 674. For example, the outlet of the conduit 630 may be disposed within the fluid storage container 674 and an additional conduit 630 may extend from the fluid storage container 674 to the vacuum source 676. Accordingly, the vacuum source 676 may apply suction to the fluid collection assembly 600 via the fluid storage container 674. The suction force may be applied directly via the vacuum source 676. For example, the outlet of the conduit 630 may be disposed within the vacuum source 676. An additional conduit 630 may extend from the vacuum source 676 to a point outside of the fluid collection assembly 600, such as to the fluid storage container 674. In such examples, the vacuum source 676 may be disposed between the fluid collection assembly 600 and the fluid storage container 674.


The fluid collection assembly 600 may be similar or identical to any of the fluid collection assemblies disclosed herein in one or more aspects. The fluid collection assembly 600 may be shaped and sized to be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough (e.g., receive a penis therein). For example, the fluid collection assembly 600 may include a fluid impermeable barrier at least partially defining a chamber (e.g., interior region) of the fluid collection assembly 600. The fluid impermeable barrier also defines at least one opening extending therethrough from the external environment. The opening may be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough. The fluid collection assembly 600 may include porous material disposed in the chamber such as one or more of a fluid permeable support and a fluid permeable membrane. The fluid collection assembly 600 includes one or more of any of the securement bodies disclosed herein.


The fluid storage container 674 is sized and shaped to retain the bodily fluids therein. The fluid storage container 674 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluids such as urine. In some examples, the conduit 630 may extend from the fluid collection assembly 600 and attach to the fluid storage container 674 at a first point therein. An additional conduit 630 may attach to the fluid storage container 674 at a second point thereon and may extend and attach to the vacuum source 676. Accordingly, a vacuum (e.g., suction) may be drawn through fluid collection assembly 600 via the fluid storage container 674. Fluid, such as urine, may be drained from the fluid collection assembly 600 using the vacuum source 676.


The vacuum source 676 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 676 may provide a vacuum or suction to remove fluid from the fluid collection assembly 600. In some examples, the vacuum source 676 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 676 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 600. For example, the vacuum source 676 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 676 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 676.


While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.


Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean±10%, ±5%, or ±2% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more protrusions extending therefrom, is oblong, is the same as the disclosed shape, etc.

Claims
  • 1. A fluid collection assembly, comprising: a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet; at least one porous material disposed in the chamber; and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient, the at least one securement body including: a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, the plurality of fibers extend from at least one exterior surface of the fluid collection assembly, at least most of the plurality of fibers extend from the at least one exterior surface at an average angle that is oblique relative to the at least one exterior surface, the at least one securement body further including a plurality of branches extending from or attached to at least some of the plurality of fibers, at least some of the plurality of branches exhibiting an average diameter of 300 nm to 2 μm, one or more of the plurality of branches extending from or attached to a portion of one of the plurality of fibers that is spaced from a terminal end of the one of the plurality of fibers, wherein the terminal end of the one of the plurality of fibers is an end of the one of the plurality of fibers farthest spaced from the at least one exterior surface.
  • 2. The fluid collection assembly of claim 1, further comprising a base and a sheath, the base including a substrate having a top surface and a bottom surface opposite the top surface, the top surface attached to one or more other components of the fluid collection assembly, the bottom surface attached to the at least one securement body.
  • 3. The fluid collection assembly of claim 1, wherein the at least one securement body is attached to or integrally formed with at least a portion of a surface of the fluid impermeable barrier that is opposite the at least one opening.
  • 4. The fluid collection assembly of claim 1, wherein the at least one securement body includes a support attached to one or more components of the fluid collection assembly, the plurality of fibers extending from the support.
  • 5. The fluid collection assembly of claim 1, wherein the plurality of fibers are directly attached to one of: at least one outer surface of the fluid impermeable barrier, wherein the at least one outer surface is opposite a surface of the fluid impermeable barrier that defines the chamber; or a bottom surface of a base, wherein the base includes a top surface opposite the bottom surface, a portion of the top surface attached to a sheath, the sheath including the fluid impermeable barrier.
  • 6. The fluid collection assembly of claim 1, wherein the plurality of fibers are integrally formed with one of: at least one outer surface of the fluid impermeable barrier, wherein the at least one outer surface is opposite a surface of the fluid impermeable barrier that defines the chamber; or a bottom surface of a base, wherein the base includes a top surface opposite the bottom surface, a portion of the top surface attached to a sheath, the sheath including the fluid impermeable barrier.
  • 7. The fluid collection assembly of claim 1, wherein the average angle is less than 45°.
  • 8. The fluid collection assembly of claim 1, wherein the at least one securement body includes a support attached to and distinct from a substrate, the plurality of fibers attached to or integrally formed with the support.
  • 9. The fluid collection assembly of claim 1, wherein: the at least one opening includes an elongated opening configured to be positioned adjacent to female anatomy; the at least one porous material extends across the elongated opening; and the at least one securement body is positioned adjacent at least to portions of the fluid impermeable barrier defining the elongated opening, at least the portion of the at least one securement body adjacent to the elongated opening including the plurality of fibers.
  • 10. The fluid collection assembly of claim 2, wherein: the at least one opening includes an elongated opening configured to be positioned adjacent to female anatomy; the at least one porous material extends across the elongated opening; and the at least one securement body is positioned adjacent at least to portions of the fluid impermeable barrier opposite the elongated opening, at least the portion of the at least one securement body opposite the elongated opening including the plurality of fibers.
  • 11. The fluid collection assembly of claim 1, wherein at least some of the plurality of branches exhibit an average diameter of 500 nm to 2 μm.
  • 12. A fluid collection system, comprising: a fluid storage container configured to hold one or more bodily fluids therein; a fluid collection assembly including: a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet; at least one porous material disposed in the chamber; and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient, the at least one securement body including: a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, the plurality of fibers extend from at least one exterior surface of the fluid collection assembly, at least most of the plurality of fibers extend from the at least one exterior surface at an average angle that is oblique relative to the at least one exterior surface, the at least one securement body further including a plurality of branches extending from or attached to at least some of the plurality of fibers, at least some of the plurality of branches exhibiting an average diameter of 300 nm to 2 μm, one or more of the plurality of branches extending from or attached to a portion of one of the plurality of fibers that is spaced from a terminal end of the one of the plurality of fibers, wherein the terminal end of the one of the plurality of fibers is an end of the one of the plurality of fibers farthest spaced from the at least one exterior surface; and a vacuum source in fluid communication with the fluid storage container and the fluid collection assembly, the vacuum source configured to draw the one or more bodily fluids from the fluid collection assembly and deposit the one or more bodily fluids in the fluid storage container via one or more conduits.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 63/134,450 filed on Jan. 6, 2021, the disclosure of which is incorporated herein, in its entirety, by this reference.

US Referenced Citations (1012)
Number Name Date Kind
737443 Mooers Aug 1903 A
1032841 Koenig Jul 1912 A
1178644 Johnson Apr 1916 A
1387726 Karge Aug 1921 A
1742080 Jones Dec 1929 A
1979899 Obrien et al. Nov 1934 A
2241010 Chipley May 1941 A
2262772 Peder Nov 1941 A
2326881 Packer Aug 1943 A
2379346 Farrell Jun 1945 A
2485555 Bester Oct 1949 A
2571357 Charles Oct 1951 A
2613670 Edward Oct 1952 A
2616426 Adele Nov 1952 A
2644234 Earl Jul 1953 A
2648335 Chambers Aug 1953 A
2859786 Tupper Nov 1958 A
2944551 Carl Jul 1960 A
2968046 Duke Jan 1961 A
2971512 Reinhardt Feb 1961 A
3032038 Swinn May 1962 A
3077883 Hill Feb 1963 A
3087938 Hans et al. Apr 1963 A
3169528 Knox et al. Feb 1965 A
3171506 Therkel Mar 1965 A
3194238 Breece Jul 1965 A
3198994 Hildebrandt et al. Aug 1965 A
3221742 Egon Dec 1965 A
3312221 Overment Apr 1967 A
3312981 McGuire et al. Apr 1967 A
3349768 Keane Oct 1967 A
3362590 Gene Jan 1968 A
3366116 Huck Jan 1968 A
3398848 Donovan Aug 1968 A
3400717 Bruce et al. Sep 1968 A
3406688 Bruce Oct 1968 A
3424163 Gravdahl Jan 1969 A
3425471 Yates Feb 1969 A
3511241 Lee May 1970 A
3512185 Ellis May 1970 A
3520300 Flower Jul 1970 A
3528423 Lee Sep 1970 A
3613123 Langstrom Oct 1971 A
3648700 Warner Mar 1972 A
3651810 Ormerod Mar 1972 A
3661155 Lindan May 1972 A
3683918 Pizzella Aug 1972 A
3699815 Holbrook Oct 1972 A
3726277 Hirschman Apr 1973 A
3742952 Magers et al. Jul 1973 A
3757355 Allen et al. Sep 1973 A
3788324 Lim Jan 1974 A
3843016 Bornhorst et al. Oct 1974 A
3863638 Rogers et al. Feb 1975 A
3863798 Kurihara et al. Feb 1975 A
3864759 Horiuchi Feb 1975 A
3865109 Elmore et al. Feb 1975 A
3881486 Fenton May 1975 A
3881489 Hartwell May 1975 A
3915189 Holbrook et al. Oct 1975 A
3998228 Poidomani Dec 1976 A
3999550 Martin Dec 1976 A
4015604 Csillag Apr 1977 A
4020843 Kanall May 1977 A
4022213 Stein May 1977 A
4027776 Douglas Jun 1977 A
4064962 Hunt Dec 1977 A
4116197 Bermingham Sep 1978 A
4180178 Turner Dec 1979 A
4187953 Turner Feb 1980 A
4194508 Anderson Mar 1980 A
4200102 Duhamel et al. Apr 1980 A
4202058 Anderson May 1980 A
4203503 Bertotti et al. May 1980 A
4209076 Bertotti et al. Jun 1980 A
4223677 Anderson Sep 1980 A
4233025 Larson et al. Nov 1980 A
4233978 Hickey Nov 1980 A
4246901 Frosch et al. Jan 1981 A
4253542 Ruspa et al. Mar 1981 A
4257418 Hessner Mar 1981 A
4270539 Frosch et al. Jun 1981 A
4281655 Terauchi Aug 1981 A
4292916 Bradley et al. Oct 1981 A
4330239 Gannaway May 1982 A
4352356 Tong Oct 1982 A
4360933 Kimura et al. Nov 1982 A
4365363 Windauer Dec 1982 A
4375841 Vielbig Mar 1983 A
4387726 Denard Jun 1983 A
4403991 Hill Sep 1983 A
4425130 Desmarais Jan 1984 A
4446986 Bowen et al. May 1984 A
4453938 Brendling Jun 1984 A
4457314 Knowles Jul 1984 A
4476879 Jackson Oct 1984 A
4526688 Schmidt et al. Jul 1985 A
4528703 Kraus Jul 1985 A
D280438 Wendt Sep 1985 S
4551141 McNeil Nov 1985 A
4553968 Komis Nov 1985 A
4581026 Schneider Apr 1986 A
4589516 Inoue et al. May 1986 A
4601716 Smith Jul 1986 A
4610675 Triunfol Sep 1986 A
4620333 Ritter Nov 1986 A
4626250 Schneider Dec 1986 A
4627846 Ternstroem Dec 1986 A
4631061 Martin Dec 1986 A
4650477 Johnson Mar 1987 A
4655754 Richmond et al. Apr 1987 A
4656675 Fajnsztajn Apr 1987 A
4681570 Dalton Jul 1987 A
4681577 Stern et al. Jul 1987 A
4692160 Nussbaumer Sep 1987 A
4707864 Ikematsu et al. Nov 1987 A
4713065 Koot Dec 1987 A
4713066 Komis Dec 1987 A
4723953 Pratt et al. Feb 1988 A
4735841 Sourdet Apr 1988 A
4743236 Manschot May 1988 A
4747166 Kuntz May 1988 A
4752944 Conrads et al. Jun 1988 A
4769215 Ehrenkranz Sep 1988 A
4771484 Mozell Sep 1988 A
4772280 Rooyakkers Sep 1988 A
4784654 Beecher Nov 1988 A
4790830 Hamacher Dec 1988 A
4790835 Elias Dec 1988 A
4791686 Taniguchi et al. Dec 1988 A
4795449 Schneider et al. Jan 1989 A
4798603 Meyer et al. Jan 1989 A
4799928 Crowley Jan 1989 A
4804377 Hanifl et al. Feb 1989 A
4812053 Bhattacharjee Mar 1989 A
4813943 Smith Mar 1989 A
4820297 Kaufman et al. Apr 1989 A
4846818 Keldahl et al. Jul 1989 A
4846909 Klug et al. Jul 1989 A
4865595 Heyden Sep 1989 A
4880417 Yabrov et al. Nov 1989 A
4882794 Stewart Nov 1989 A
4883465 Brennan Nov 1989 A
4886498 Newton Dec 1989 A
4886508 Washington Dec 1989 A
4886509 Mattsson Dec 1989 A
4889532 Metz et al. Dec 1989 A
4889533 Beecher Dec 1989 A
4890691 Ching-ho Jan 1990 A
4903254 Haas Feb 1990 A
4904248 Vaillancourt Feb 1990 A
4905692 More Mar 1990 A
4936838 Cross et al. Jun 1990 A
4955922 Terauchi Sep 1990 A
4957487 Gerow Sep 1990 A
4965460 Tanaka et al. Oct 1990 A
4986823 Anderson et al. Jan 1991 A
4987849 Sherman Jan 1991 A
5002541 Conkling et al. Mar 1991 A
5004463 Nigay Apr 1991 A
5031248 Kemper Jul 1991 A
5045077 Blake Sep 1991 A
5045283 Patel Sep 1991 A
5049144 Payton Sep 1991 A
5053339 Patel Oct 1991 A
5057092 Webster Oct 1991 A
5058088 Haas et al. Oct 1991 A
5071347 McGuire Dec 1991 A
5078707 Peter Jan 1992 A
5084037 Barnett Jan 1992 A
5100396 Zamierowski Mar 1992 A
5112324 Wallace May 1992 A
5147301 Ruvio Sep 1992 A
5176667 Debring Jan 1993 A
5195997 Carns Mar 1993 A
5196654 Diflora et al. Mar 1993 A
5203699 McGuire Apr 1993 A
5244458 Takasu Sep 1993 A
5246454 Peterson Sep 1993 A
5267988 Farkas Dec 1993 A
5275307 Freese Jan 1994 A
5282795 Finney Feb 1994 A
5294983 Ersoz et al. Mar 1994 A
5295983 Kubo Mar 1994 A
5300052 Kubo Apr 1994 A
5304749 Crandell Apr 1994 A
5312383 Kubalak May 1994 A
5318550 Cermak et al. Jun 1994 A
5330459 Lavon et al. Jul 1994 A
5340840 Park et al. Aug 1994 A
5382244 Telang Jan 1995 A
5409014 Napoli et al. Apr 1995 A
5411495 Willingham May 1995 A
5423784 Metz Jun 1995 A
5456246 Schmieding et al. Oct 1995 A
5466229 Elson et al. Nov 1995 A
5478334 Bernstein Dec 1995 A
5499977 Marx Mar 1996 A
5543042 Filan et al. Aug 1996 A
D373928 Green Sep 1996 S
5582604 Ahr et al. Dec 1996 A
5592950 Kopelowicz Jan 1997 A
5605161 Cross Feb 1997 A
5618277 Goulter Apr 1997 A
5628735 Skow May 1997 A
5636643 Argenta et al. Jun 1997 A
5637104 Ball et al. Jun 1997 A
5674212 Osborn et al. Oct 1997 A
5678564 Lawrence et al. Oct 1997 A
5678654 Uzawa Oct 1997 A
5687429 Rahlff Nov 1997 A
5695485 Duperret et al. Dec 1997 A
5700254 Mcdowall et al. Dec 1997 A
5701612 Daneshvar Dec 1997 A
5705777 Flanigan et al. Jan 1998 A
5752944 Dann et al. May 1998 A
5763333 Suzuki et al. Jun 1998 A
5772644 Bark et al. Jun 1998 A
5792132 Garcia Aug 1998 A
5827243 Palestrant Oct 1998 A
5827247 Kay Oct 1998 A
5827250 Fujioka et al. Oct 1998 A
5827257 Fujioka et al. Oct 1998 A
D401699 Herchenbach et al. Nov 1998 S
5859393 Cummins et al. Jan 1999 A
5865378 Hollinshead et al. Feb 1999 A
5876393 Ahr et al. Mar 1999 A
5887291 Bellizzi Mar 1999 A
5891125 Plumley Apr 1999 A
5894608 Birbara Apr 1999 A
D409303 Oepping May 1999 S
5911222 Lawrence et al. Jun 1999 A
5957904 Holland Sep 1999 A
5968026 Osborn et al. Oct 1999 A
5972505 Phillips et al. Oct 1999 A
6007526 Passalaqua et al. Dec 1999 A
6039060 Rower Mar 2000 A
6050983 Moore et al. Apr 2000 A
6059762 Boyer et al. May 2000 A
6063064 Tuckey et al. May 2000 A
6098625 Winkler Aug 2000 A
6105174 Karlsten et al. Aug 2000 A
6113582 Dwork Sep 2000 A
6117163 Bierman Sep 2000 A
6123398 Arai et al. Sep 2000 A
6129718 Wada et al. Oct 2000 A
6131964 Sareshwala Oct 2000 A
6152902 Christian et al. Nov 2000 A
6164569 Hollinshead et al. Dec 2000 A
6177606 Etheredge et al. Jan 2001 B1
6209142 Mattsson et al. Apr 2001 B1
6220050 Cooksey Apr 2001 B1
6244311 Hand et al. Jun 2001 B1
6248096 Dwork et al. Jun 2001 B1
6263887 Dunn Jul 2001 B1
6283246 Nishikawa Sep 2001 B1
6311339 Kraus Nov 2001 B1
6336919 Davis et al. Jan 2002 B1
6338729 Wada et al. Jan 2002 B1
6352525 Wakabayashi Mar 2002 B1
6394988 Hashimoto May 2002 B1
6398742 Kim Jun 2002 B1
6406463 Brown Jun 2002 B1
6409712 Dutari et al. Jun 2002 B1
6416500 Wada et al. Jul 2002 B1
6423045 Wise et al. Jul 2002 B1
6428521 Droll Aug 2002 B1
6428522 Dipalma et al. Aug 2002 B1
6446454 Lee et al. Sep 2002 B1
6475198 Lipman et al. Nov 2002 B1
6479726 Cole et al. Nov 2002 B1
6491673 Palumbo et al. Dec 2002 B1
6508794 Palumbo et al. Jan 2003 B1
6524292 Dipalma et al. Feb 2003 B1
6540729 Wada et al. Apr 2003 B1
6547771 Robertson et al. Apr 2003 B2
6569133 Cheng et al. May 2003 B2
D476518 Doppelt Jul 2003 S
6592560 Snyder et al. Jul 2003 B2
6610038 Dipalma et al. Aug 2003 B1
6618868 Minnick Sep 2003 B2
6620142 Flueckiger Sep 2003 B1
6629651 Male et al. Oct 2003 B1
6635038 Scovel Oct 2003 B2
6652495 Walker Nov 2003 B1
6666850 Ahr et al. Dec 2003 B1
6685684 Falconer Feb 2004 B1
6695828 Dipalma et al. Feb 2004 B1
6699174 Bennett Mar 2004 B1
6700034 Lindsay et al. Mar 2004 B1
6702793 Sweetser et al. Mar 2004 B1
6706027 Harvie et al. Mar 2004 B2
6732384 Scott May 2004 B2
6736977 Hall et al. May 2004 B1
6740066 Wolff et al. May 2004 B2
6764477 Chen et al. Jul 2004 B1
6783519 Samuelsson Aug 2004 B2
6796974 Palumbo et al. Sep 2004 B2
6814547 Childers et al. Nov 2004 B2
6849065 Schmidt et al. Feb 2005 B2
6857137 Otto Feb 2005 B2
6885690 Aggerstam et al. Apr 2005 B2
6888044 Fell et al. May 2005 B2
6893425 Dunn et al. May 2005 B2
6912737 Ernest et al. Jul 2005 B2
6918899 Harvie Jul 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7018366 Easter Mar 2006 B2
7066411 Male et al. Jun 2006 B2
7122023 Hinoki Oct 2006 B1
7125399 Miskie Oct 2006 B2
7131964 Harvie Nov 2006 B2
7135012 Harvie Nov 2006 B2
7141043 Harvie Nov 2006 B2
D533972 La Dec 2006 S
7160273 Greter et al. Jan 2007 B2
7171699 Ernest et al. Feb 2007 B2
7171871 Kozak Feb 2007 B2
7179951 Krishnaswamy-Mirle et al. Feb 2007 B2
7181781 Trabold et al. Feb 2007 B1
7186245 Cheng et al. Mar 2007 B1
7192424 Cooper Mar 2007 B2
7219764 Forbes May 2007 B1
7220250 Suzuki et al. May 2007 B2
D562975 Otto Feb 2008 S
7335189 Harvie Feb 2008 B2
7358282 Krueger et al. Apr 2008 B2
7390320 Machida et al. Jun 2008 B2
7438706 Koizumi et al. Oct 2008 B2
7488310 Yang Feb 2009 B2
7491194 Oliwa Feb 2009 B1
D591106 Dominique et al. Apr 2009 S
7513381 Heng et al. Apr 2009 B2
7520872 Biggie et al. Apr 2009 B2
D593801 Wilson et al. Jun 2009 S
7540364 Sanderson Jun 2009 B2
7549511 Marocco Jun 2009 B2
7549512 Newberry Jun 2009 B2
7585293 Vermaak Sep 2009 B2
7588560 Dunlop Sep 2009 B1
7637905 Saadat et al. Dec 2009 B2
7665359 Barber Feb 2010 B2
7682347 Parks et al. Mar 2010 B2
7687004 Allen Mar 2010 B2
7695459 Gilbert et al. Apr 2010 B2
7695460 Wada et al. Apr 2010 B2
7699818 Gilbert Apr 2010 B2
7699831 Bengtson et al. Apr 2010 B2
7722584 Tanaka et al. May 2010 B2
7727206 Gorres Jun 2010 B2
7740620 Gilbert et al. Jun 2010 B2
7749205 Tazoe et al. Jul 2010 B2
7755497 Wada et al. Jul 2010 B2
7766887 Burns et al. Aug 2010 B2
D625407 Koizumi et al. Oct 2010 S
7806879 Brooks et al. Oct 2010 B2
7811272 Lindsay Oct 2010 B2
7815067 Matsumoto et al. Oct 2010 B2
7833169 Hannon Nov 2010 B2
7857806 Karpowicz et al. Dec 2010 B2
7866942 Harvie Jan 2011 B2
7871385 Levinson et al. Jan 2011 B2
7875010 Frazier et al. Jan 2011 B2
7901389 Mombrinie Mar 2011 B2
7927320 Goldwasser et al. Apr 2011 B2
7927321 Marland Apr 2011 B2
7931634 Swiecicki et al. Apr 2011 B2
7939706 Okabe et al. May 2011 B2
7946443 Stull et al. May 2011 B2
7947025 Buglino et al. May 2011 B2
7963419 Burney et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
7993318 Olsson et al. Aug 2011 B2
8015627 Baker et al. Sep 2011 B2
8016071 Martinus et al. Sep 2011 B1
8028460 Williams Oct 2011 B2
8047398 Dimartino et al. Nov 2011 B2
8083094 Caulfield et al. Dec 2011 B2
8128608 Thevenin Mar 2012 B2
8181651 Pinel May 2012 B2
8181819 Burney et al. May 2012 B2
8211063 Bierman et al. Jul 2012 B2
8221369 Parks et al. Jul 2012 B2
8241262 Mahnensmith Aug 2012 B2
8277426 Wilcox et al. Oct 2012 B2
8287508 Sanchez Oct 2012 B1
8303554 Tsai et al. Nov 2012 B2
8322565 Caulfield et al. Dec 2012 B2
8337477 Parks et al. Dec 2012 B2
D674241 Bickert et al. Jan 2013 S
8343122 Gorres Jan 2013 B2
8343125 Kawazoe et al. Jan 2013 B2
8353074 Krebs Jan 2013 B2
8353886 Bester et al. Jan 2013 B2
D676241 Merrill Feb 2013 S
8388588 Wada et al. Mar 2013 B2
D679807 Burgess et al. Apr 2013 S
8425482 Khoubnazar Apr 2013 B2
8434586 Pawelski et al. May 2013 B2
8449510 Martini et al. May 2013 B2
D684260 Lund et al. Jun 2013 S
8470230 Caulfield et al. Jun 2013 B2
8479941 Matsumoto et al. Jul 2013 B2
8479949 Henkel Jul 2013 B2
8500719 Simpson et al. Aug 2013 B1
8512301 Ma Aug 2013 B2
8529530 Koch et al. Sep 2013 B2
8535284 Joder et al. Sep 2013 B2
8546639 Wada et al. Oct 2013 B2
8551075 Bengtson Oct 2013 B2
8568376 Delattre et al. Oct 2013 B2
D694404 Burgess et al. Nov 2013 S
8585683 Bengtson et al. Nov 2013 B2
8586583 Hamblin et al. Nov 2013 B2
8652112 Johannison et al. Feb 2014 B2
8669412 Fernkvist et al. Mar 2014 B2
D702973 Norland et al. Apr 2014 S
8703032 Menon et al. Apr 2014 B2
D704330 Cicatelli May 2014 S
D704510 Mason et al. May 2014 S
D705423 Walsh Cutler May 2014 S
D705926 Burgess et al. May 2014 S
8714394 Wulf May 2014 B2
8715267 Bengtson et al. May 2014 B2
8757425 Copeland Jun 2014 B2
8777032 Biesecker et al. Jul 2014 B2
8808260 Koch et al. Aug 2014 B2
8864730 Conway et al. Oct 2014 B2
8881923 Higginson Nov 2014 B2
8882731 Suzuki et al. Nov 2014 B2
8936585 Carson et al. Jan 2015 B2
D729581 Boroski May 2015 S
9028460 Medeiros May 2015 B2
9056698 Noer Jun 2015 B2
9078792 Ruiz Jul 2015 B2
9145879 Pirovano et al. Sep 2015 B2
9173602 Gilbert Nov 2015 B2
9173799 Tanimoto et al. Nov 2015 B2
9187220 Biesecker et al. Nov 2015 B2
9199772 Krippendorf Dec 2015 B2
9233020 Matsumiya Jan 2016 B2
9248058 Conway et al. Feb 2016 B2
9308118 Dupree et al. Apr 2016 B1
9309029 Incorvia et al. Apr 2016 B2
9333281 Giezendanner et al. May 2016 B2
9381108 Longoni et al. Jul 2016 B2
9382047 Schmidtner et al. Jul 2016 B2
9402424 Roy Aug 2016 B2
9456937 Ellis Oct 2016 B2
9480595 Baham et al. Nov 2016 B2
9517865 Albers et al. Dec 2016 B2
D777941 Piramoon Jan 2017 S
9533806 Ding et al. Jan 2017 B2
9550611 Hodge Jan 2017 B2
9555930 Campbell et al. Jan 2017 B2
9623159 Locke Apr 2017 B2
D789522 Burgess et al. Jun 2017 S
9687849 Bruno et al. Jun 2017 B2
9694949 Hendricks et al. Jul 2017 B2
9709048 Kinjo Jul 2017 B2
9713547 Lee et al. Jul 2017 B2
9732754 Huang et al. Aug 2017 B2
9752564 Arceno et al. Sep 2017 B2
9788992 Harvie Oct 2017 B2
D804907 Sandoval Dec 2017 S
9868564 McGirr et al. Jan 2018 B2
D814239 Arora Apr 2018 S
D817484 Lafond May 2018 S
10037640 Gordon Jul 2018 B2
10058470 Phillips Aug 2018 B2
10098990 Koch et al. Oct 2018 B2
D835264 Mozzicato et al. Dec 2018 S
D835779 Mozzicato et al. Dec 2018 S
D840533 Mozzicato et al. Feb 2019 S
D840534 Mozzicato et al. Feb 2019 S
10225376 Perez Martinez Mar 2019 B2
10226376 Sanchez et al. Mar 2019 B2
10258517 Maschino et al. Apr 2019 B1
D848612 Mozzicato et al. May 2019 S
10307305 Hodges Jun 2019 B1
10335121 Desai Jul 2019 B2
D856512 Cowart et al. Aug 2019 S
10376406 Newton Aug 2019 B2
10376407 Newton Aug 2019 B2
10390989 Sanchez et al. Aug 2019 B2
D858144 Fu Sep 2019 S
10406039 Mllarreal Sep 2019 B2
10407222 Allen Sep 2019 B2
10478356 Griffin Nov 2019 B2
10500108 Maschino et al. Dec 2019 B1
10538366 Pentelovitch et al. Jan 2020 B2
10569938 Zhao et al. Feb 2020 B2
10577156 Dagnelie et al. Mar 2020 B2
RE47930 Cho Apr 2020 E
10618721 Vazin Apr 2020 B2
D884390 Wang May 2020 S
10669079 Freedman et al. Jun 2020 B2
D892315 Airy Aug 2020 S
10730672 Bertram et al. Aug 2020 B2
10737848 Philip et al. Aug 2020 B2
10765854 Law et al. Sep 2020 B2
10766670 Kittmann Sep 2020 B2
10799386 Harrison Oct 2020 B1
10806642 Tagomori et al. Oct 2020 B2
D901214 Hu Nov 2020 S
10849799 Nishikawa et al. Dec 2020 B2
10857025 Davis et al. Dec 2020 B2
10865017 Cowart et al. Dec 2020 B1
10889412 West et al. Jan 2021 B2
10913581 Stahlecker Feb 2021 B2
D912244 Rehm et al. Mar 2021 S
10952889 Newton et al. Mar 2021 B2
10973378 Ryu et al. Apr 2021 B2
10973678 Newton et al. Apr 2021 B2
10974874 Ragias et al. Apr 2021 B2
11000401 Ecklund et al. May 2021 B2
D923365 Wang Jun 2021 S
11026829 Harvie Jun 2021 B2
11027900 Liu Jun 2021 B2
11045346 Argent et al. Jun 2021 B2
D928946 Sanchez et al. Aug 2021 S
11090183 Sanchez et al. Aug 2021 B2
11160695 Febo et al. Nov 2021 B2
11160697 Maschino et al. Nov 2021 B2
11168420 Kinugasa et al. Nov 2021 B2
11179506 Barr et al. Nov 2021 B2
11226376 Yamauchi et al. Jan 2022 B2
11253407 Miao et al. Feb 2022 B2
11326586 Milner et al. May 2022 B2
11369508 Ecklund et al. Jun 2022 B2
11369524 Hubbard et al. Jun 2022 B2
11376152 Sanchez et al. Jul 2022 B2
11382786 Sanchez et al. Jul 2022 B2
11382788 Hjorth et al. Jul 2022 B2
11389318 Radl et al. Jul 2022 B2
11395871 Radl et al. Jul 2022 B2
11399990 Suyama Aug 2022 B2
11426303 Davis et al. Aug 2022 B2
11504265 Godinez et al. Nov 2022 B2
11529252 Glithero et al. Dec 2022 B2
11547788 Radl et al. Jan 2023 B2
11806266 Sanchez et al. Nov 2023 B2
11839567 Davis et al. Dec 2023 B2
D1010109 Ecklund et al. Jan 2024 S
11857716 Lee et al. Jan 2024 B2
11865030 Davis et al. Jan 2024 B2
11890221 Ulreich et al. Feb 2024 B2
11925575 Newton Mar 2024 B2
11938053 Austermann et al. Mar 2024 B2
11944740 Hughett et al. Apr 2024 B2
12023457 Mann et al. Jul 2024 B2
12042422 Davis et al. Jul 2024 B2
20010037097 Cheng et al. Nov 2001 A1
20010054426 Knudson et al. Dec 2001 A1
20020019614 Woon Feb 2002 A1
20020026161 Grundke Feb 2002 A1
20020087131 Wolff et al. Jul 2002 A1
20020091364 Prabhakar Jul 2002 A1
20020189992 Schmidt et al. Dec 2002 A1
20020193760 Thompson Dec 2002 A1
20030004436 Schmidt et al. Jan 2003 A1
20030032931 Grundke et al. Feb 2003 A1
20030032944 Cawood Feb 2003 A1
20030073964 Palumbo et al. Apr 2003 A1
20030120178 Heki Jun 2003 A1
20030157859 Ishikawa Aug 2003 A1
20030181880 Schwartz Sep 2003 A1
20030195484 Harvie Oct 2003 A1
20030204173 Burns et al. Oct 2003 A1
20030233079 Parks et al. Dec 2003 A1
20040006321 Cheng et al. Jan 2004 A1
20040015141 Cheng et al. Jan 2004 A1
20040056122 Male et al. Mar 2004 A1
20040084465 Luburic May 2004 A1
20040127872 Petryk et al. Jul 2004 A1
20040128749 Scott Jul 2004 A1
20040143229 Easter Jul 2004 A1
20040147863 Diaz et al. Jul 2004 A1
20040147894 Mizutani et al. Jul 2004 A1
20040158221 Mizutani et al. Aug 2004 A1
20040176731 Cheng et al. Sep 2004 A1
20040176746 Forral Sep 2004 A1
20040191919 Unger et al. Sep 2004 A1
20040200936 Opperthauser Oct 2004 A1
20040207530 Nielsen Oct 2004 A1
20040236292 Tazoe et al. Nov 2004 A1
20040243075 Harvie Dec 2004 A1
20040254547 Okabe et al. Dec 2004 A1
20050010182 Parks et al. Jan 2005 A1
20050033248 Machida et al. Feb 2005 A1
20050065471 Kuntz Mar 2005 A1
20050070861 Okabe et al. Mar 2005 A1
20050070862 Tazoe et al. Mar 2005 A1
20050082300 Modrell et al. Apr 2005 A1
20050097662 Leimkuhler et al. May 2005 A1
20050101924 Elson et al. May 2005 A1
20050119630 Harvie Jun 2005 A1
20050137557 Swiecicki et al. Jun 2005 A1
20050154360 Harvie Jul 2005 A1
20050177070 Levinson et al. Aug 2005 A1
20050197639 Mombrinie Sep 2005 A1
20050273920 Marinas Dec 2005 A1
20050277904 Chase et al. Dec 2005 A1
20050279359 Leblanc et al. Dec 2005 A1
20060004332 Marx Jan 2006 A1
20060015080 Mahnensmith Jan 2006 A1
20060015081 Suzuki et al. Jan 2006 A1
20060016778 Park Jan 2006 A1
20060069359 Dipalma et al. Mar 2006 A1
20060079854 Kay et al. Apr 2006 A1
20060111648 Vermaak May 2006 A1
20060155214 Wightman Jul 2006 A1
20060171997 Gruenbacher et al. Aug 2006 A1
20060200102 Cooper Sep 2006 A1
20060229575 Boiarski Oct 2006 A1
20060229576 Conway et al. Oct 2006 A1
20060231648 Male et al. Oct 2006 A1
20060235266 Nan Oct 2006 A1
20060235359 Marland Oct 2006 A1
20060241553 Harvie Oct 2006 A1
20060269439 White Nov 2006 A1
20060277670 Baker et al. Dec 2006 A1
20070006368 Key et al. Jan 2007 A1
20070010797 Nishtala et al. Jan 2007 A1
20070016152 Karpowicz et al. Jan 2007 A1
20070038194 Wada et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070073252 Forgrave Mar 2007 A1
20070117880 Elson et al. May 2007 A1
20070118993 Bates May 2007 A1
20070135786 Schmidt et al. Jun 2007 A1
20070137718 Rushlander et al. Jun 2007 A1
20070149935 Dirico Jun 2007 A1
20070191804 Coley Aug 2007 A1
20070203464 Green et al. Aug 2007 A1
20070214553 Carromba et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070225666 Otto Sep 2007 A1
20070225668 Otto Sep 2007 A1
20070266486 Ramirez Nov 2007 A1
20070282309 Bengtson et al. Dec 2007 A1
20080004576 Tanaka et al. Jan 2008 A1
20080015526 Reiner et al. Jan 2008 A1
20080015527 House Jan 2008 A1
20080033386 Okabe et al. Feb 2008 A1
20080041869 Backaert Feb 2008 A1
20080091153 Harvie Apr 2008 A1
20080091158 Yang Apr 2008 A1
20080114327 Barge May 2008 A1
20080167634 Kouta et al. Jul 2008 A1
20080183157 Walters Jul 2008 A1
20080215031 Belfort et al. Sep 2008 A1
20080234642 Patterson et al. Sep 2008 A1
20080269703 Collins et al. Oct 2008 A1
20080281282 Finger et al. Nov 2008 A1
20080287894 Van Den Heuvel et al. Nov 2008 A1
20080312550 Nishtala et al. Dec 2008 A1
20090025717 Pinel Jan 2009 A1
20090048570 Jensen Feb 2009 A1
20090056003 Ivie et al. Mar 2009 A1
20090069761 Vogel Mar 2009 A1
20090069765 Wortham Mar 2009 A1
20090120179 Nylander et al. May 2009 A1
20090192482 Dodge et al. Jul 2009 A1
20090234312 Otoole et al. Sep 2009 A1
20090251510 Noro et al. Oct 2009 A1
20090264840 Mrginio Oct 2009 A1
20090270822 Medeiros Oct 2009 A1
20090281510 Fisher Nov 2009 A1
20100004612 Thevenin Jan 2010 A1
20100058660 Williams Mar 2010 A1
20100121289 Parks et al. May 2010 A1
20100158168 Murthy et al. Jun 2010 A1
20100160882 Lowe Jun 2010 A1
20100174250 Hu et al. Jul 2010 A1
20100185168 Graauw et al. Jul 2010 A1
20100198172 Wada et al. Aug 2010 A1
20100211032 Tsai et al. Aug 2010 A1
20100234820 Tsai et al. Sep 2010 A1
20100241104 Gilbert Sep 2010 A1
20100263113 Shelton et al. Oct 2010 A1
20100310845 Bond et al. Dec 2010 A1
20110028920 Johannison Feb 2011 A1
20110028922 Kay et al. Feb 2011 A1
20110034889 Smith Feb 2011 A1
20110036837 Shang Feb 2011 A1
20110040267 Wada et al. Feb 2011 A1
20110040271 Rogers et al. Feb 2011 A1
20110054426 Stewart et al. Mar 2011 A1
20110060299 Wada et al. Mar 2011 A1
20110060300 Weig et al. Mar 2011 A1
20110077495 Gilbert Mar 2011 A1
20110077606 Wilcox et al. Mar 2011 A1
20110087337 Forsell Apr 2011 A1
20110137273 Muellejans et al. Jun 2011 A1
20110145993 Rader et al. Jun 2011 A1
20110152802 Dicamillo et al. Jun 2011 A1
20110164147 Takahashi et al. Jul 2011 A1
20110172620 Khambatta Jul 2011 A1
20110172625 Wada et al. Jul 2011 A1
20110202024 Cozzens Aug 2011 A1
20110238023 Slayton Sep 2011 A1
20110240648 Tucker Oct 2011 A1
20110251572 Nishtala et al. Oct 2011 A1
20110265889 Tanaka et al. Nov 2011 A1
20110276020 Mitsui Nov 2011 A1
20120029452 Roedsten Feb 2012 A1
20120035577 Tomes et al. Feb 2012 A1
20120041400 Christensen Feb 2012 A1
20120059328 Dikeman et al. Mar 2012 A1
20120066825 Birbara et al. Mar 2012 A1
20120103347 Wheaton et al. May 2012 A1
20120137420 Gordon et al. Jun 2012 A1
20120165768 Sekiyama et al. Jun 2012 A1
20120165786 Chappa et al. Jun 2012 A1
20120210503 Anzivino et al. Aug 2012 A1
20120233761 Huang Sep 2012 A1
20120245541 Suzuki et al. Sep 2012 A1
20120245542 Suzuki et al. Sep 2012 A1
20120245547 Wilcox et al. Sep 2012 A1
20120253303 Suzuki et al. Oct 2012 A1
20120271259 Ulert Oct 2012 A1
20120296305 Barraza Khaled et al. Nov 2012 A1
20120316522 Carter et al. Dec 2012 A1
20120330256 Wilcox et al. Dec 2012 A1
20130006206 Wada et al. Jan 2013 A1
20130045651 Esteves et al. Feb 2013 A1
20130053804 Soerensen et al. Feb 2013 A1
20130096523 Chang et al. Apr 2013 A1
20130110059 Kossow et al. May 2013 A1
20130138064 Stroebech et al. May 2013 A1
20130150813 Gordon et al. Jun 2013 A1
20130218112 Thompson Aug 2013 A1
20130245496 Wells et al. Sep 2013 A1
20130245586 Jha Sep 2013 A1
20130292537 Dirico Nov 2013 A1
20130330501 Aizenberg Dec 2013 A1
20140005647 Shuffler et al. Jan 2014 A1
20140031774 Bengtson Jan 2014 A1
20140039432 Dunbar et al. Feb 2014 A1
20140157499 Suzuki et al. Jun 2014 A1
20140171889 Hopman et al. Jun 2014 A1
20140182051 Tanimoto et al. Jul 2014 A1
20140196189 Lee et al. Jul 2014 A1
20140276501 Cisko Sep 2014 A1
20140303582 Wright et al. Oct 2014 A1
20140316381 Reglin Oct 2014 A1
20140325746 Block Nov 2014 A1
20140348139 Gomez Martinez Nov 2014 A1
20140352050 Yao et al. Dec 2014 A1
20140371628 Desai Dec 2014 A1
20150045757 Lee et al. Feb 2015 A1
20150047114 Ramirez Feb 2015 A1
20150048089 Robertson Feb 2015 A1
20150135423 Sharpe et al. May 2015 A1
20150157300 Ealovega et al. Jun 2015 A1
20150209194 Heyman Jul 2015 A1
20150290425 Macy et al. Oct 2015 A1
20150320583 Harvie Nov 2015 A1
20150329255 Rzepecki Nov 2015 A1
20150342799 Michiels et al. Dec 2015 A1
20150359660 Harvie Dec 2015 A1
20150366699 Nelson Dec 2015 A1
20160029998 Brister et al. Feb 2016 A1
20160030228 Jones Feb 2016 A1
20160038356 Yao et al. Feb 2016 A1
20160058322 Brister et al. Mar 2016 A1
20160060001 Wada et al. Mar 2016 A1
20160100976 Conway et al. Apr 2016 A1
20160106604 Timm Apr 2016 A1
20160113809 Kim Apr 2016 A1
20160183689 Miner Jun 2016 A1
20160256022 Le Sep 2016 A1
20160270982 Raycheck et al. Sep 2016 A1
20160278662 Brister et al. Sep 2016 A1
20160357400 Penha et al. Dec 2016 A1
20160366699 Zhang et al. Dec 2016 A1
20160367226 Newton et al. Dec 2016 A1
20160367411 Justiz et al. Dec 2016 A1
20160367726 Gratzer Dec 2016 A1
20160374848 Sanchez et al. Dec 2016 A1
20170007438 Harvie Jan 2017 A1
20170014560 Minskoff et al. Jan 2017 A1
20170100276 Joh Apr 2017 A1
20170128638 Giezendanner et al. May 2017 A1
20170136209 Burnett et al. May 2017 A1
20170143534 Sanchez May 2017 A1
20170165100 Jackson et al. Jun 2017 A1
20170165405 Muser et al. Jun 2017 A1
20170189225 Voorhees et al. Jul 2017 A1
20170202692 Laniado Jul 2017 A1
20170216081 Accosta Aug 2017 A1
20170246026 Laniado Aug 2017 A1
20170252014 Siller Gonzalez et al. Sep 2017 A1
20170252202 Sanchez et al. Sep 2017 A9
20170266031 Sanchez et al. Sep 2017 A1
20170266658 Bruno et al. Sep 2017 A1
20170281399 Vanmiddendorp et al. Oct 2017 A1
20170312116 Laniado Nov 2017 A1
20170325788 Ealovega et al. Nov 2017 A1
20170333244 Laniado Nov 2017 A1
20170042748 Griffin Dec 2017 A1
20170348139 Newton et al. Dec 2017 A1
20170354532 Holt Dec 2017 A1
20170354551 Gawley et al. Dec 2017 A1
20170367873 Grannum Dec 2017 A1
20180002075 Lee Jan 2018 A1
20180008451 Stroebech Jan 2018 A1
20180008804 Laniado Jan 2018 A1
20180021218 Brosch et al. Jan 2018 A1
20180028349 Newton et al. Feb 2018 A1
20180037384 Archeny et al. Feb 2018 A1
20180049910 Newton Feb 2018 A1
20180064572 Wiltshire Mar 2018 A1
20180104131 Killian Apr 2018 A1
20180127187 Sewell May 2018 A1
20180193215 Davies et al. Jul 2018 A1
20180200101 Su Jul 2018 A1
20180228642 Davis et al. Aug 2018 A1
20180256384 Kasirye Sep 2018 A1
20180271694 Fernandez et al. Sep 2018 A1
20180317892 Catlin Nov 2018 A1
20180325748 Sharma et al. Nov 2018 A1
20190001030 Braga et al. Jan 2019 A1
20190021899 Vlet Jan 2019 A1
20190038451 Harvie Feb 2019 A1
20190046102 Kushnir et al. Feb 2019 A1
20190059938 Holsten Feb 2019 A1
20190091059 Gabriel Mar 2019 A1
20190100362 Meyers et al. Apr 2019 A1
20190133814 Tammen et al. May 2019 A1
20190142624 Sanchez et al. May 2019 A1
20190224036 Sanchez et al. Jul 2019 A1
20190247222 Ecklund et al. Aug 2019 A1
20190247223 Brun et al. Aug 2019 A1
20190282391 Johannes Sep 2019 A1
20190314189 Acosta Oct 2019 A1
20190314190 Sanchez et al. Oct 2019 A1
20190321587 Mcmenamin et al. Oct 2019 A1
20190344934 Faerber et al. Nov 2019 A1
20190365307 Laing et al. Dec 2019 A1
20190365561 Newton et al. Dec 2019 A1
20200008985 Nguyen et al. Jan 2020 A1
20200016012 Dutkiewicz Jan 2020 A1
20200030595 Boukidjian et al. Jan 2020 A1
20200046544 Godinez et al. Feb 2020 A1
20200055638 Lau et al. Feb 2020 A1
20200070392 Huber et al. Mar 2020 A1
20200085609 Schelch et al. Mar 2020 A1
20200085610 Cohn et al. Mar 2020 A1
20200086090 Von Weymarn-Schärli et al. Mar 2020 A1
20200107518 Hiroshima et al. Apr 2020 A1
20200129322 Leuckel Apr 2020 A1
20200171217 Braga et al. Jun 2020 A9
20200206039 Mclain Jul 2020 A1
20200214910 Varona et al. Jul 2020 A1
20200216898 Hubbell Jul 2020 A1
20200216989 Kinugasa et al. Jul 2020 A1
20200229964 Staali et al. Jul 2020 A1
20200231343 Freedman et al. Jul 2020 A1
20200232841 Satish et al. Jul 2020 A1
20200246172 Ho Aug 2020 A1
20200246203 Tulk et al. Aug 2020 A1
20200255189 Liu Aug 2020 A1
20200261280 Heyman Aug 2020 A1
20200276046 Staali et al. Sep 2020 A1
20200306075 Newton et al. Oct 2020 A1
20200315837 Radl et al. Oct 2020 A1
20200315838 Eckert Oct 2020 A1
20200315872 Viens et al. Oct 2020 A1
20200315874 Viens et al. Oct 2020 A1
20200331672 Bertram et al. Oct 2020 A1
20200345332 Duval Nov 2020 A1
20200353135 Gregory et al. Nov 2020 A1
20200367677 Silsby et al. Nov 2020 A1
20200369444 Silsby et al. Nov 2020 A1
20200375781 Staali et al. Dec 2020 A1
20200375810 Carlin et al. Dec 2020 A1
20200385179 Mccourt Dec 2020 A1
20200390591 Glithero et al. Dec 2020 A1
20200390592 Merrill Dec 2020 A1
20200405521 Glasroe Dec 2020 A1
20210008771 Huber et al. Jan 2021 A1
20210009323 Markarian et al. Jan 2021 A1
20210020072 Moehring et al. Jan 2021 A1
20210059853 Davis et al. Mar 2021 A1
20210061523 Bytheway Mar 2021 A1
20210069005 Sanchez et al. Mar 2021 A1
20210069008 Blabas et al. Mar 2021 A1
20210069009 Im Mar 2021 A1
20210069030 Nishikawa et al. Mar 2021 A1
20210077993 Nazareth et al. Mar 2021 A1
20210113749 Radl et al. Apr 2021 A1
20210121318 Pinlac Apr 2021 A1
20210137724 Ecklund et al. May 2021 A1
20210138190 Erbey et al. May 2021 A1
20210154055 Mllarreal May 2021 A1
20210170079 Radl et al. Jun 2021 A1
20210178390 Oueslati et al. Jun 2021 A1
20210186742 Newton et al. Jun 2021 A1
20210212865 Wallajapet et al. Jul 2021 A1
20210220162 Jamison Jul 2021 A1
20210220163 Mayrand Jul 2021 A1
20210228400 Glithero Jul 2021 A1
20210228401 Becker et al. Jul 2021 A1
20210228795 Hughett et al. Jul 2021 A1
20210229877 Ragias et al. Jul 2021 A1
20210236323 Austermann et al. Aug 2021 A1
20210236324 Sweeney Aug 2021 A1
20210251814 Jönegren et al. Aug 2021 A1
20210267787 Nazemi Sep 2021 A1
20210275343 Sanchez et al. Sep 2021 A1
20210275344 Wing Sep 2021 A1
20210290454 Yamada Sep 2021 A1
20210315727 Jiang Oct 2021 A1
20210353450 Sharma et al. Nov 2021 A1
20210361469 Liu et al. Nov 2021 A1
20210369495 Cheng et al. Dec 2021 A1
20210386925 Hartwell et al. Dec 2021 A1
20210393433 Godinez et al. Dec 2021 A1
20220023091 Ecklund et al. Jan 2022 A1
20220031523 Pierpoint Feb 2022 A1
20220039995 Johannes et al. Feb 2022 A1
20220047410 Walthall Feb 2022 A1
20220062027 Mitchell et al. Mar 2022 A1
20220062028 Mitchell et al. Mar 2022 A1
20220062029 Johannes et al. Mar 2022 A1
20220066825 Saraf et al. Mar 2022 A1
20220071811 Cheng et al. Mar 2022 A1
20220071826 Kulkarni et al. Mar 2022 A1
20220104965 Vaninetti et al. Apr 2022 A1
20220104976 Hoeger et al. Apr 2022 A1
20220104981 Jones Apr 2022 A1
20220117773 Davis et al. Apr 2022 A1
20220117774 Meyer et al. Apr 2022 A1
20220117775 Jones et al. Apr 2022 A1
20220133524 Davis May 2022 A1
20220151817 Mann May 2022 A1
20220160949 Simiele et al. May 2022 A1
20220168159 Triado et al. Jun 2022 A1
20220193312 Lee et al. Jun 2022 A1
20220211536 Johannes et al. Jul 2022 A1
20220218510 Metzger et al. Jul 2022 A1
20220229053 Levin et al. Jul 2022 A1
20220241106 Johannes et al. Aug 2022 A1
20220247407 Yamamoto et al. Aug 2022 A1
20220248836 Cagle et al. Aug 2022 A1
20220257407 Johannes et al. Aug 2022 A1
20220265460 Coker Aug 2022 A1
20220265462 Alder et al. Aug 2022 A1
20220270711 Feala et al. Aug 2022 A1
20220273482 Johannes et al. Sep 2022 A1
20220280357 Jagannathan et al. Sep 2022 A1
20220287689 Johannes Sep 2022 A1
20220296408 Evans et al. Sep 2022 A1
20220305191 Joseph et al. Sep 2022 A1
20220313222 Austermann et al. Oct 2022 A1
20220313474 Kriscovich et al. Oct 2022 A1
20220331170 Erdem et al. Oct 2022 A1
20220339024 Johannes et al. Oct 2022 A1
20220354685 Davis et al. Nov 2022 A1
20220362049 Austermann et al. Nov 2022 A1
20220370231 Wang et al. Nov 2022 A1
20220370234 Hughett et al. Nov 2022 A1
20220370235 Johannes et al. Nov 2022 A1
20220370237 Parmar et al. Nov 2022 A1
20220387001 Askenazi et al. Dec 2022 A1
20220395390 Brooks Dec 2022 A1
20220395391 Saunders et al. Dec 2022 A1
20230018845 Lee Jan 2023 A1
20230020563 Sharma et al. Jan 2023 A1
20230031640 Hughett et al. Feb 2023 A1
20230037159 Brennan et al. Feb 2023 A1
20230052238 Oluwasogo Feb 2023 A1
20230062944 Vollenberg et al. Mar 2023 A1
20230062994 Ecklund et al. Mar 2023 A1
20230070347 Watson et al. Mar 2023 A1
20230073708 Xu et al. Mar 2023 A1
20230089032 Hughett et al. Mar 2023 A1
20230099821 Radl et al. Mar 2023 A1
20230099991 Bianchi et al. Mar 2023 A1
20230105001 Whittome et al. Apr 2023 A1
20230110577 Choi Apr 2023 A1
20230138269 Abdelal et al. May 2023 A1
20230145365 Martin et al. May 2023 A1
20230155253 Mn et al. May 2023 A1
20230210504 Kuroda et al. Jul 2023 A1
20230210685 Fallows et al. Jul 2023 A1
20230218426 Hughett Jul 2023 A1
20230240884 Davis et al. Aug 2023 A1
20230248562 Sanchez et al. Aug 2023 A1
20230248564 Mann et al. Aug 2023 A1
20230255812 Sanchez et al. Aug 2023 A1
20230255813 Sanchez et al. Aug 2023 A1
20230255815 Newton Aug 2023 A1
20230263650 Sanchez et al. Aug 2023 A1
20230263655 Johannes et al. Aug 2023 A1
20230277362 Davis et al. Sep 2023 A1
20230285178 Sanchez et al. Sep 2023 A1
20230293339 James Sep 2023 A1
20230301846 Greenwood Sep 2023 A1
20230355423 Stevenson et al. Nov 2023 A1
20230404791 Ecklund et al. Dec 2023 A1
20240008444 Su et al. Jan 2024 A1
20240009023 Johannes et al. Jan 2024 A1
20240024170 Scott Jan 2024 A1
20240041638 Johannes et al. Feb 2024 A1
20240058161 Ulreich et al. Feb 2024 A1
20240065881 Kuroda et al. Feb 2024 A1
20240099874 Sanchez et al. Mar 2024 A1
20240110318 Bendt et al. Apr 2024 A1
20240123134 Kharkar et al. Apr 2024 A1
Foreign Referenced Citations (447)
Number Date Country
2018216821 Aug 2019 AU
2021299304 Feb 2023 AU
2165286 Sep 1999 CA
2354132 Jun 2000 CA
2359091 Sep 2003 CA
2488867 Aug 2007 CA
3050918 Aug 2018 CA
3098571 Nov 2019 CA
2269203 Dec 1997 CN
1332620 Jan 2002 CN
1434693 Aug 2003 CN
1533755 Oct 2004 CN
1602825 Apr 2005 CN
1720888 Jan 2006 CN
2936204 Aug 2007 CN
101262836 Sep 2008 CN
101522148 Sep 2009 CN
102159159 Aug 2011 CN
202184840 Apr 2012 CN
102481441 May 2012 CN
202463712 Oct 2012 CN
103533968 Jan 2014 CN
103717180 Apr 2014 CN
204562697 Aug 2015 CN
105411783 Mar 2016 CN
105451693 Mar 2016 CN
105534632 May 2016 CN
205849719 Jan 2017 CN
106726089 May 2017 CN
107847384 Mar 2018 CN
107920912 Apr 2018 CN
108420590 Aug 2018 CN
209285902 Aug 2019 CN
110381883 Oct 2019 CN
211198839 Aug 2020 CN
112566550 Mar 2021 CN
112603184 Apr 2021 CN
114007493 Feb 2022 CN
114375187 Apr 2022 CN
116096332 May 2023 CN
79818 Oct 1893 DE
1516466 Jun 1969 DE
2721330 Nov 1977 DE
2742298 Mar 1978 DE
9407554.9 May 1995 DE
4443710 Jun 1995 DE
4416094 Nov 1995 DE
4236097 Oct 1996 DE
19619597 Nov 1997 DE
102005037762 Sep 2006 DE
102011103783 Dec 2012 DE
202015104597 Jul 2016 DE
102020121462 Jan 2022 DE
9600118 Nov 1996 DK
0032138 Jul 1981 EP
0068712 Jan 1983 EP
0140470 May 1985 EP
066070 Sep 1985 EP
0140471 May 1988 EP
0274753 Jul 1988 EP
0119143 Nov 1988 EP
0483592 May 1992 EP
0610638 Aug 1994 EP
0613355 Sep 1994 EP
0613355 Jan 1997 EP
0787472 Aug 1997 EP
0966936 Dec 1999 EP
0987293 Mar 2000 EP
1063953 Jan 2001 EP
0653928 Oct 2002 EP
1332738 Aug 2003 EP
1382318 Jan 2004 EP
1089684 Oct 2004 EP
1616542 Jan 2006 EP
1382318 May 2006 EP
1063953 Jan 2007 EP
1872752 Jan 2008 EP
2180907 May 2010 EP
2380532 Oct 2011 EP
2389908 Nov 2011 EP
2601916 Jun 2013 EP
2676643 Dec 2013 EP
2997950 Mar 2016 EP
2879534 Mar 2017 EP
3424471 Jan 2019 EP
3169292 Nov 2019 EP
3753492 Dec 2020 EP
3788992 Mar 2021 EP
3576689 Mar 2022 EP
3752110 Mar 2022 EP
3787570 Mar 2022 EP
4025163 Jul 2022 EP
3463180 Mar 2023 EP
3569205 Jun 2023 EP
4382082 Jun 2024 EP
871820 Jul 1961 GB
1011517 Dec 1965 GB
1467144 Mar 1977 GB
2106395 Apr 1983 GB
2106784 Apr 1983 GB
2148126 May 1985 GB
2171315 Aug 1986 GB
2181953 May 1987 GB
2148126 Jul 1987 GB
2191095 Dec 1987 GB
2199750 Jul 1988 GB
2260907 May 1993 GB
2462267 Feb 2010 GB
2469496 Oct 2010 GB
2490327 Oct 2012 GB
2507318 Apr 2014 GB
2612752 May 2023 GB
201800009129 Apr 2020 IT
S498638 Jan 1974 JP
S5410596 Jan 1979 JP
S5410596 May 1979 JP
S55155618 Dec 1980 JP
S5888596 Jun 1983 JP
S63107780 Jul 1988 JP
H0267530 Mar 1990 JP
H02103871 Apr 1990 JP
H02131422 May 1990 JP
H02131422 Nov 1990 JP
H0460220 Feb 1992 JP
H04060220 May 1992 JP
H05123349 May 1993 JP
H05123350 May 1993 JP
3087938 Oct 1995 JP
H085630 Jan 1996 JP
H1040141 Feb 1998 JP
H10225430 Aug 1998 JP
H11113946 Apr 1999 JP
H11290365 Oct 1999 JP
2000116690 Apr 2000 JP
2000185068 Jul 2000 JP
2001054531 Feb 2001 JP
2001070331 Mar 2001 JP
2001224616 Aug 2001 JP
2001276107 Oct 2001 JP
2001276108 Oct 2001 JP
2002028173 Jan 2002 JP
2003505152 Feb 2003 JP
2003126242 May 2003 JP
2003180722 Jul 2003 JP
2003528691 Sep 2003 JP
2004057578 Feb 2004 JP
2004130056 Apr 2004 JP
2004267530 Sep 2004 JP
2005052219 Mar 2005 JP
2005066011 Mar 2005 JP
2005066325 Mar 2005 JP
2005102978 Apr 2005 JP
2005518237 Jun 2005 JP
3749097 Dec 2005 JP
2006026108 Feb 2006 JP
3123547 Jun 2006 JP
2006136492 Jun 2006 JP
2006204868 Aug 2006 JP
2007044494 Feb 2007 JP
3132659 May 2007 JP
2007209687 Aug 2007 JP
4039641 Nov 2007 JP
2008005975 Jan 2008 JP
2009509570 Mar 2009 JP
2009165887 Jul 2009 JP
2010504150 Feb 2010 JP
2010081981 Apr 2010 JP
4640772 Dec 2010 JP
2010536439 Dec 2010 JP
2011500225 Jan 2011 JP
2011030962 Feb 2011 JP
4747166 May 2011 JP
2011087823 May 2011 JP
4801218 Aug 2011 JP
2011218130 Nov 2011 JP
2011224070 Nov 2011 JP
3175719 Apr 2012 JP
2012523869 Oct 2012 JP
2013238608 Nov 2013 JP
2014521960 Aug 2014 JP
2015092945 May 2015 JP
3198994 Jul 2015 JP
2016521191 Jul 2016 JP
2017014698 Jan 2017 JP
2019525811 Sep 2019 JP
2019170942 Oct 2019 JP
2019533492 Nov 2019 JP
2021120686 Aug 2021 JP
2021522009 Aug 2021 JP
2021522013 Aug 2021 JP
7129493 Aug 2022 JP
2023532132 Jul 2023 JP
200290061 Sep 2002 KR
20030047451 Jun 2003 KR
20140039485 Apr 2014 KR
101432639 Aug 2014 KR
20180106659 Oct 2018 KR
20180108774 Oct 2018 KR
2068717 Jun 2013 PT
505542 Sep 1997 SE
8101957 Jul 1981 WO
8804558 Jun 1988 WO
9104714 Apr 1991 WO
9104714 Jun 1991 WO
9220299 Feb 1993 WO
9307839 Apr 1993 WO
9309736 May 1993 WO
9309736 Jun 1993 WO
9514448 Jun 1995 WO
9600096 Jan 1996 WO
9634636 Nov 1996 WO
9817211 Apr 1998 WO
9830336 Jul 1998 WO
0000112 Jan 2000 WO
0000113 Jan 2000 WO
0025651 May 2000 WO
0033773 Jun 2000 WO
0057784 Oct 2000 WO
0069377 Nov 2000 WO
0079497 Dec 2000 WO
0145618 Jun 2001 WO
0145621 Jun 2001 WO
02094160 Nov 2002 WO
03013967 Feb 2003 WO
03024824 Mar 2003 WO
03055423 Jul 2003 WO
03071931 Sep 2003 WO
03079942 Oct 2003 WO
03071931 Feb 2004 WO
2004019836 Mar 2004 WO
2004024046 Mar 2004 WO
2004026195 Apr 2004 WO
2005051252 Jun 2005 WO
2005074571 Sep 2005 WO
2005089687 Sep 2005 WO
2005107661 Nov 2005 WO
2006021220 Mar 2006 WO
2006037140 Apr 2006 WO
2007005851 Jan 2007 WO
2007007845 Jan 2007 WO
2007042823 Apr 2007 WO
2007055651 May 2007 WO
2006098950 Nov 2007 WO
2007134608 Nov 2007 WO
2007128156 Feb 2008 WO
2008026106 Mar 2008 WO
2008078117 Jul 2008 WO
2008104019 Sep 2008 WO
2008141471 Nov 2008 WO
2009004368 Jan 2009 WO
2009004369 Jan 2009 WO
2009052496 Apr 2009 WO
2009052502 Apr 2009 WO
2009007702 Jul 2009 WO
2009101738 Aug 2009 WO
2010058192 May 2010 WO
2010030122 Jul 2010 WO
2010101915 Jan 2011 WO
2011018132 Feb 2011 WO
2011018133 Feb 2011 WO
2011024864 Mar 2011 WO
2011054118 May 2011 WO
2011079132 Jun 2011 WO
2011107972 Sep 2011 WO
2011108972 Sep 2011 WO
2011117292 Sep 2011 WO
2011123219 Oct 2011 WO
2011132043 Oct 2011 WO
2012012908 Feb 2012 WO
2012065274 May 2012 WO
2012097462 Jul 2012 WO
2012098796 Jul 2012 WO
2012101288 Aug 2012 WO
2012175916 Dec 2012 WO
2013018435 Feb 2013 WO
2013033429 Mar 2013 WO
2013055434 Apr 2013 WO
2013082397 Jun 2013 WO
2013103291 Jul 2013 WO
2013131109 Sep 2013 WO
2013167478 Nov 2013 WO
2013177716 Dec 2013 WO
2014041534 Mar 2014 WO
2014046420 Mar 2014 WO
2014118518 Aug 2014 WO
2014160852 Oct 2014 WO
2015023599 Feb 2015 WO
2015052348 Apr 2015 WO
2015068384 May 2015 WO
2015169403 Nov 2015 WO
2015170307 Nov 2015 WO
2015197462 Dec 2015 WO
2016051385 Apr 2016 WO
2016055989 Apr 2016 WO
2016071894 May 2016 WO
2016103242 Jun 2016 WO
2016116915 Jul 2016 WO
2016124203 Aug 2016 WO
2016139448 Sep 2016 WO
2016166562 Oct 2016 WO
2016167535 Oct 2016 WO
2016191574 Dec 2016 WO
2016200088 Dec 2016 WO
2016200361 Dec 2016 WO
2016204731 Dec 2016 WO
2017001532 Jan 2017 WO
2017001846 Jan 2017 WO
2017075226 May 2017 WO
2017152198 Sep 2017 WO
2017153357 Sep 2017 WO
2017162559 Sep 2017 WO
2017205446 Nov 2017 WO
2017209779 Dec 2017 WO
2017210524 Dec 2017 WO
2018022414 Feb 2018 WO
2018044781 Mar 2018 WO
2018056953 Mar 2018 WO
2018090550 May 2018 WO
2018138513 Aug 2018 WO
2018144318 Aug 2018 WO
2018144463 Aug 2018 WO
2018150263 Aug 2018 WO
2018150268 Aug 2018 WO
2018152156 Aug 2018 WO
2018183791 Oct 2018 WO
2018150267 Nov 2018 WO
2018235026 Dec 2018 WO
2018235065 Dec 2018 WO
2019004404 Jan 2019 WO
2019041005 Mar 2019 WO
2019044217 Mar 2019 WO
2019044218 Mar 2019 WO
2019044219 Mar 2019 WO
2019050959 Mar 2019 WO
2019065541 Apr 2019 WO
2019096845 May 2019 WO
2019150385 Aug 2019 WO
2019161094 Aug 2019 WO
2019188566 Oct 2019 WO
2019190593 Oct 2019 WO
2019212949 Nov 2019 WO
2019212950 Nov 2019 WO
2019212951 Nov 2019 WO
2019212952 Nov 2019 WO
2019212954 Nov 2019 WO
2019212955 Nov 2019 WO
2019212956 Nov 2019 WO
2019214787 Nov 2019 WO
2019214788 Nov 2019 WO
2019226826 Nov 2019 WO
2019239433 Dec 2019 WO
2020000994 Jan 2020 WO
2020020618 Jan 2020 WO
2020038822 Feb 2020 WO
2020088409 May 2020 WO
2020049394 Jun 2020 WO
2020120657 Jun 2020 WO
2020152575 Jul 2020 WO
2020182923 Sep 2020 WO
2020204967 Oct 2020 WO
2020205939 Oct 2020 WO
2020209898 Oct 2020 WO
2020242790 Dec 2020 WO
2020251893 Dec 2020 WO
2020256865 Dec 2020 WO
2021007144 Jan 2021 WO
2021007345 Jan 2021 WO
2021010844 Jan 2021 WO
2021016026 Jan 2021 WO
2021016300 Jan 2021 WO
2021025919 Feb 2021 WO
2021034886 Feb 2021 WO
2021041123 Mar 2021 WO
2021046501 Mar 2021 WO
2021086868 May 2021 WO
2021094352 May 2021 WO
2021094639 May 2021 WO
2021097067 May 2021 WO
2021102296 May 2021 WO
2021107025 Jun 2021 WO
2021138411 Jul 2021 WO
2021138414 Jul 2021 WO
2021154686 Aug 2021 WO
2021155206 Aug 2021 WO
2021170075 Sep 2021 WO
2021173436 Sep 2021 WO
2021188817 Sep 2021 WO
2021195384 Sep 2021 WO
2021205995 Oct 2021 WO
2021207621 Oct 2021 WO
2021211568 Oct 2021 WO
2021211801 Oct 2021 WO
2021211914 Oct 2021 WO
2021216419 Oct 2021 WO
2021216422 Oct 2021 WO
2021231532 Nov 2021 WO
2021247523 Dec 2021 WO
2021257202 Dec 2021 WO
2022006256 Jan 2022 WO
2022031943 Feb 2022 WO
2022035745 Feb 2022 WO
2022051360 Mar 2022 WO
2022054613 Mar 2022 WO
2022066704 Mar 2022 WO
2022067392 Apr 2022 WO
2022069950 Apr 2022 WO
2022071429 Apr 2022 WO
2022076322 Apr 2022 WO
2022076427 Apr 2022 WO
2022086898 Apr 2022 WO
2022090199 May 2022 WO
2022098536 May 2022 WO
2022099087 May 2022 WO
2022101999 May 2022 WO
2022115692 Jun 2022 WO
2022125685 Jun 2022 WO
2022140545 Jun 2022 WO
2022145231 Jul 2022 WO
2022150360 Jul 2022 WO
2022150463 Jul 2022 WO
2022159392 Jul 2022 WO
2022170182 Aug 2022 WO
2022182385 Sep 2022 WO
2022187152 Sep 2022 WO
2022192188 Sep 2022 WO
2022192347 Sep 2022 WO
2022204000 Sep 2022 WO
2022216507 Oct 2022 WO
2022222030 Oct 2022 WO
2023286058 Jan 2023 WO
2023014639 Feb 2023 WO
2023014641 Feb 2023 WO
2023018475 Feb 2023 WO
2023023777 Mar 2023 WO
2023034453 Mar 2023 WO
2023038945 Mar 2023 WO
2023038950 Mar 2023 WO
2023049109 Mar 2023 WO
2023049175 Mar 2023 WO
2023086394 May 2023 WO
2023149884 Aug 2023 WO
2023149902 Aug 2023 WO
2023149903 Aug 2023 WO
2023154390 Aug 2023 WO
2023191764 Oct 2023 WO
2023244238 Dec 2023 WO
2024058788 Mar 2024 WO
Non-Patent Literature Citations (796)
Entry
US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn)
International Search Report and Written Opinion from International Application No. PCT/US2022/015781 mailed May 6, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/016942 mailed Jun. 8, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/018159 mailed Dec. 12, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/018170 mailed May 31, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/019254 mailed Jun. 7, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/019480 mailed Jun. 13, 2022.
Non-Final Office Action for U.S. Appl. No. 17/501,591 mailed Apr. 25, 2023.
Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Apr. 7, 2023.
Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 14, 2023.
Non-Final Office Action for U.S. Appl. No. 17/662,700 mailed Jul. 22, 2022.
Non-Final Office Action for U.S. Appl. No. 29/741,751 mailed Jan. 18, 2022.
Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Dec. 15, 2022.
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2022.
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Aug. 10, 2022.
Advisory Action for U.S. Appl. No. 16/245,726 mailed Apr. 19, 2023.
Advisory Action for U.S. Appl. No. 16/369,676 mailed Mar. 24, 2023.
Advisory Action for U.S. Appl. No. 16/433,773 mailed Feb. 15, 2023.
Advisory Action for U.S. Appl. No. 16/452,258 mailed Oct. 26, 2022.
Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 21, 2022.
Advisory Action for U.S. Appl. No. 16/904,868 mailed Jun. 15, 2022.
Advisory Action for U.S. Appl. No. 16/905,400 mailed Feb. 16, 2022.
Advisory Action for U.S. Appl. No. 17/662,700 mailed Jan. 30, 2023.
Final Office Action for U.S. Appl. No. 16/245,726 mailed Nov. 25, 2022.
Final Office Action for U.S. Appl. No. 16/369,676 mailed Dec. 5, 2022.
Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 25, 2022.
Final Office Action for U.S. Appl. No. 16/449,039 mailed Aug. 1, 2022.
Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 25, 2022.
Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 14, 2022.
Final Office Action for U.S. Appl. No. 16/478,180 mailed Jun. 22, 2022.
Final Office Action for U.S. Appl. No. 16/478,180 mailed May 31, 2023.
Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 10, 2022.
Final Office Action for U.S. Appl. No. 17/051,399 mailed Mar. 9, 2023.
Final Office Action for U.S. Appl. No. 17/051,550 mailed May 23, 2023.
Final Office Action for U.S. Appl. No. 17/451,345 mailed May 3, 2023.
Final Office Action for U.S. Appl. No. 17/662,700 mailed Sep. 30, 2022.
International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 mailed Nov. 5, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2020/057562 mailed Jan. 27, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/026607 mailed Jul. 29, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/039866 mailed Oct. 7, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/045188 mailed Jan. 26, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/047536 mailed Dec. 23, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/048211 mailed Dec. 22, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/048661 mailed Feb. 14, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/049404 mailed Jan. 18, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/051456 mailed Jan. 19, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/053593 mailed Apr. 11, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/055515 mailed Jan. 28, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/056566 mailed Feb. 11, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/060993 mailed Mar. 18, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2021/062440 mailed Mar. 28, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/011108 mailed Apr. 22, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/011281 mailed Apr. 25, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/011419 mailed Jun. 7, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/011421 mailed Jun. 13, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/012794 mailed May 3, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/014285 mailed Sep. 28, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/014749 mailed Sep. 28, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015026 mailed Oct. 31, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015045 mailed Sep. 9, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015073 mailed Sep. 8, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015418 mailed Nov. 11, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015420 mailed Nov. 18, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015471 mailed May 16, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/015492 mailed Apr. 26, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/021103 mailed Jun. 23, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/022111 mailed Oct. 26, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/023594 mailed Jul. 12, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/026667 mailed Aug. 22, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/030685 mailed Oct. 31, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/031032 mailed Sep. 9, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/032424 mailed Oct. 11, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/034457 mailed Oct. 12, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/034744 mailed Dec. 9, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/039018 mailed Jan. 10, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/039022 mailed Jan. 10, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/039711 mailed Jan. 12, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/039714 mailed Nov. 22, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/041085 mailed Mar. 16, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/041688 mailed Nov. 21, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/042719 mailed Dec. 5, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/042725 mailed Dec. 19, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/044107 mailed Dec. 23, 2022.
International Search Report and Written Opinion from International Application No. PCT/US2022/044212 mailed Jan. 20, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/044243 mailed Feb. 24, 2023.
Issue Notification for U.S. Appl. No. 16/899,956 mailed Mar. 29, 2023.
Issue Notification for U.S. Appl. No. 16/905,400 mailed Nov. 30, 2022.
Issue Notification for U.S. Appl. No. 17/088,272 mailed Jun. 15, 2022.
Issue Notification for U.S. Appl. No. 17/330,657 mailed Jun. 22, 2022.
Non-Final Office Action for U.S. Appl. No. 16/245,726 mailed Jan. 21, 2022.
Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Mar. 31, 2022.
Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 11, 2023.
Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 21, 2022.
Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Apr. 27, 2023.
Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 28, 2023.
Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Apr. 26, 2023.
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Dec. 20, 2022.
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 15, 2023.
Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 27, 2022.
Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Dec. 15, 2022.
Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Mar. 29, 2023.
Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Mar. 24, 2023.
Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Feb. 10, 2023.
Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Apr. 13, 2023.
Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Mar. 1, 2023.
Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 10, 2023.
Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Dec. 7, 2022.
Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed May 3, 2023.
Non-Final Office Action for U.S. Appl. No. 17/453,260 mailed Mar. 14, 2023.
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 1, 2022.
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 29, 2021.
Notice of Allowance for U.S. Appl. No. 16/905,400 mailed Aug. 17, 2022.
Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Mar. 4, 2022.
Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Mar. 16, 2022.
Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Feb. 22, 2023.
Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Oct. 6, 2022.
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 28, 2023.
Notice of Allowance for U.S. Appl. No. 17/663,046 mailed Jan. 30, 2023.
Notice of Allowance for U.S. Appl. No. 29/741,751 mailed Jun. 9, 2022.
Restriction Requirement for U.S. Appl. No. 17/326,980 mailed Mar. 20, 2023.
Restriction Requirement for U.S. Appl. No. 17/446,256 mailed Jan. 23, 2023.
Restriction Requirement for U.S. Appl. No. 17/646,771 mailed Apr. 6, 2023.
Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022.
U.S. Application No. 15/384, 196 filed Dec. 19, 2016.
U.S. Appl. No. 17/394,055, filed Aug. 4, 2021.
U.S. Appl. No. 17/597,408, filed Jan. 5, 2022.
U.S. Appl. No. 17/597,673, filed Jan. 18, 2022.
U.S. Appl. No. 17/631,619, filed Jan. 31, 2022.
U.S. Appl. No. 17/653,314, filed Mar. 3, 2022.
U.S. Appl. No. 17/653,920, filed Mar. 8, 2022.
U.S. Appl. No. 17/655,464, filed Mar. 18, 2022.
U.S. Appl. No. 17/657,474, filed Mar. 31, 2022.
U.S. Appl. No. 17/661,090, filed Apr. 28, 2022.
U.S. Appl. No. 17/662,700, filed May 10, 2022.
U.S. Appl. No. 17/663,046, filed May 12, 2022.
U.S. Appl. No. 17/664,914, filed May 25, 2022.
U.S. Appl. No. 17/749,340, filed May 20, 2022.
U.S. Appl. No. 17/754,736, filed Apr. 11, 2022.
U.S. Appl. No. 17/756,201, filed May 19, 2022.
U.S. Appl. No. 17/758,152 filed Jun. 29, 2022.
U.S. Appl. No. 17/758,316, filed Jul. 1, 2022.
U.S. Appl. No. 17/759,697, filed Jul. 28, 2022.
U.S. Appl. No. 17/878,268, filed Aug. 1, 2022.
U.S. Appl. No. 17/907,125, filed Sep. 23, 2022.
U.S. Appl. No. 17/912,147, filed Sep. 16, 2022.
U.S. Appl. No. 17/929,887, filed Sep. 6, 2022.
U.S. Appl. No. 17/930,238, filed Sep. 7, 2022.
U.S. Appl. No. 17/933,590, filed Sep. 20, 2022.
U.S. Appl. No. 17/996,064, filed Oct. 12, 2022.
U.S. Appl. No. 17/996,155, filed Oct. 13, 2022.
U.S. Appl. No. 17/996,253, filed Oct. 14, 2022.
U.S. Appl. No. 17/996,468, filed Oct. 18, 2022.
U.S. Appl. No. 17/996,556, filed Oct. 19, 2022.
U.S. Appl. No. 18/003,029, filed Dec. 22, 2022.
U.S. Appl. No. 18/006,807, filed Jan. 25, 2023.
U.S. Appl. No. 18/007,105, filed Jan. 27, 2023.
U.S. Appl. No. 18/041,109, filed Feb. 9, 2023.
U.S. Appl. No. 18/042,842, filed Feb. 24, 2023.
U.S. Appl. No. 18/043,618, filed Mar. 1, 2023.
U.S. Appl. No. 18/115,444, filed Feb. 28, 2023.
U.S. Appl. No. 18/134,857, filed Apr. 14, 2023.
U.S. Appl. No. 18/140,163 filed Apr. 27, 2023.
U.S. Appl. No. 18/140,751, filed Apr. 28, 2023.
U.S. Appl. No. 18/164,800, filed Feb. 6, 2023.
U.S. Appl. No. 18/198,464, filed May 17, 2023.
U.S. Appl. No. 18/246,121 filed Mar. 21, 2023.
U.S. Appl. No. 18/247,986, filed Apr. 5, 2023.
U.S. Appl. No. 18/299,788, filed Apr. 13, 2023.
U.S. Appl. No. 62/923,279, filed Oct. 18, 2019.
U.S. Appl. No. 62/926,767, filed Oct. 28, 2019.
U.S. Appl. No. 62/935,337, filed Nov. 14, 2019.
U.S. Appl. No. 62/967,158, filed Jan. 26, 2020.
U.S. Appl. No. 62/967,977, filed Jan. 30, 2020.
U.S. Appl. No. 62/991,754, filed Mar. 19, 2020.
U.S. Appl. No. 63/008,112, filed Apr. 10, 2020.
U.S. Appl. No. 63/094,646, filed Oct. 21, 2020.
U.S. Appl. No. 63/138,878, filed Jan. 19, 2021.
U.S. Appl. No. 63/191,558, filed May 21, 2021.
U.S. Appl. No. 63/192,289, filed May 24, 2021.
U.S. Appl. No. 63/208,262, filed Jun. 8, 2021.
U.S. Appl. No. 63/230,897, filed Aug. 9, 2021.
U.S. Appl. No. 63/241,328, filed Sep. 7, 2021.
U.S. Appl. No. 63/299,208, filed Jan. 13, 2022.
U.S. Appl. No. 63/308,190, filed Feb. 9, 2022.
PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022, 72 pages.
PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022, 99 pages.
PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022, 106 pages.
PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022, 115 pages.
PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022, 117 pages.
“AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page.
“AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages.
“AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages.
“Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages.
“GSA Price List”, Omni Medical, Apr. 2011, 2 pages.
“How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages.
“Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages.
“Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages.
“Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages.
“Urine Bag Cover-Catheter Bag Cover 2000 ml Volume-Medline Style-Multiple Sclerosis-Spine Injury-Suprapublic Catheter-Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page.
“Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages.
Ali , “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31.
Autumn , et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579.
Cañas , et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288.
Chaudhary , et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440.
Dai , et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334.
Espinoza-Ramirez , “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019.
Hwang , et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20.
Jagota , et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292.
Jeong , et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644.
Jeong , et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346.
Karp , et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43.
Lee , et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5.
Parness , et al., “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232.
Pieper , et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55.
Tsipenyuk , et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of The Royal Society—Interface, 2014, pp. 1-6.
Vinas , “A Solution For An Awkward—But Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021, 3 pages.
Advisory Action for U.S. Appl. No. 14/722,613 mailed Mar. 4, 2019.
Advisory Action for U.S. Appl. No. 14/952,591 mailed Jun. 1, 2018.
Advisory Action for U.S. Appl. No. 15/238,427 mailed Apr. 10, 2019.
Advisory Action for U.S. Appl. No. 16/899,956 mailed Jul. 9, 2021.
Advisory Action for U.S. Appl. No. 16/904,868 mailed Jul. 2, 2021.
Advisory Action for U.S. Appl. No. 16/905,400 mailed Jun. 9, 2021.
Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 mailed Jan. 11, 2018.
Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 mailed Jul. 2, 2019.
Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 mailed Mar. 17, 2021.
Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 mailed Dec. 9, 2021.
Final Office Action for U.S. Appl. No. 14/722,613 mailed on Nov. 29, 2018.
Final Office Action for U.S. Appl. No. 14/947,759 mailed Apr. 8, 2016.
Final Office Action for U.S. Appl. No. 14/952,591 mailed Feb. 23, 2018.
Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 1, 2019.
Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 27, 2020.
Final Office Action for U.S. Appl. No. 15/171,968 mailed Feb. 14, 2020.
Final Office Action for U.S. Appl. No. 15/171,968 mailed Mar. 19, 2019.
Final Office Action for U.S. Appl. No. 15/221,106 mailed Jan. 23, 2019.
Final Office Action for U.S. Appl. No. 15/238,427 mailed Jan. 2, 2019.
Final Office Action for U.S. Appl. No. 15/260,103 mailed Feb. 14, 2019.
Final Office Action for U.S. Appl. No. 15/612,325 mailed Sep. 17, 2020.
Final Office Action for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2021.
Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 26, 2021.
Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 6, 2021.
Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 9, 2021.
Final Office Action for U.S. Appl. No. 17/088,272 mailed May 25, 2021.
Final Office Action for U.S. Appl. No. 29/624,661 mailed Feb. 18, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2016/049274 mailed Dec. 1, 2016.
International Search Report and Written Opinion from International Application No. PCT/US2017/035625 mailed Aug. 15, 2017.
International Search Report and Written Opinion from International Application No. PCT/US2017/043025 mailed Oct. 18, 2017.
International Search Report and Written Opinion from International Application No. PCT/US2018/015968 mailed Apr. 6, 2018.
International Search Report and Written Opinion from International Application No. PCT/US2019/029608 mailed Sep. 3, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2019/029609 mailed Sep. 3, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2019/029610 mailed Sep. 3, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2019/029611 mailed Jul. 3, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2019/029613 mailed Jul. 3, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2019/029614 mailed Sep. 26, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2019/029616 mailed Aug. 30, 2019.
International Search Report and Written Opinion from International Application No. PCT/US2020/023572 mailed Jul. 6, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/033064 mailed Aug. 31, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/033122 mailed Aug. 31, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/040860 mailed Oct. 2, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/041242 mailed Nov. 17, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/041249 mailed Oct. 2, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/042262 mailed Oct. 14, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/043059 mailed Oct. 6, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/044024 mailed Nov. 12, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/046914 mailed Dec. 1, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/055680 mailed Dec. 15, 2020.
International Search Report and Written Opinion from International Application No. PCT/US2020/061563 mailed Feb. 19, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2020/065234 mailed Apr. 12, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2020/067451 mailed Mar. 25, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2020/067454 mailed Mar. 29, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2020/067455 mailed Mar. 26, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/015024 mailed May 18, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/015787 mailed May 27, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/023001 mailed Jun. 21, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/024162 mailed Jul. 8, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027061 mailed Jul. 19, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027104 mailed Jul. 6, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027314 mailed Jul. 6, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027422 mailed Aug. 12, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027425 mailed Aug. 11, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027913 mailed Jul. 12, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/027917 mailed Aug. 19, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/035181 mailed Sep. 16, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/043893 mailed Nov. 22, 2021.
International Search Report and Written Opinion from International Application No. PCT/US2021/044699 mailed Nov. 22, 2021.
Issue Notification for U.S. Appl. No. 14/952,591 mailed Jul. 28, 2021.
Issue Notification for U.S. Appl. No. 15/171,968 mailed Mar. 3, 2021.
Issue Notification for U.S. Appl. No. 15/221,106 mailed Jul. 24, 2019.
Issue Notification for U.S. Appl. No. 15/238,427 mailed Jul. 24, 2019.
Issue Notification for U.S. Appl. No. 15/260,103 mailed Aug. 7, 2019.
Issue Notification for U.S. Appl. No. 15/611,587 mailed Feb. 20, 2019.
Issue Notification for U.S. Appl. No. 15/612,325 mailed Mar. 24, 2021.
Issue Notification for U.S. Appl. No. 29/624,661 mailed Aug. 4, 2021.
Non-Final Office Action for U.S. Appl. No. 14/592,591 mailed Mar. 20, 2020.
Non-Final Office Action for U.S. Appl. No. 14/722,613 mailed Jun. 13, 2019.
Non-Final Office Action for U.S. Appl. No. 14/947,759 mailed Mar. 17, 2016.
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Aug. 1, 2017.
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 20, 2020.
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 21, 2019.
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Sep. 28, 2018.
Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed May 11, 2020.
Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Aug. 20, 2019.
Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Jun. 12, 2018.
Non-Final Office Action for U.S. Appl. No. 15/221,106 mailed Jun. 5, 2018.
Non-Final Office Action for U.S. Appl. No. 15/238,427 mailed Aug. 8, 2018.
Non-Final Office Action for U.S. Appl. No. 15/260,103 mailed Sep. 26, 2018.
Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Dec. 29, 2017.
Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Jul. 13, 2018.
Non-Final Office Action for U.S. Appl. No. 15/612,325 mailed Mar. 19, 2020.
Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Dec. 8, 2021.
Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Sep. 28, 2021.
Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Sep. 28, 2021.
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Oct. 22, 2021.
Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Oct. 16, 2020.
Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Sep. 2, 2021.
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 25, 2020.
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Oct. 5, 2021.
Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 2, 2020.
Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Jul. 22, 2021.
Non-Final Office Action for U.S. Appl. No. 17/088,272 mailed Jan. 25, 2021.
Non-Final Office Action for U.S. Appl. No. 17/330,657 mailed Aug. 11, 2021.
Non-Final Office Action for U.S. Appl. No. 29/624,661 mailed Jul. 18, 2019.
Non-Final Office Action for U.S. Appl. No. 29/694,002 mailed Jun. 24, 2020.
Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Apr. 5, 2021.
Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Jul. 8, 2021.
Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Feb. 16, 2021.
Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Nov. 6, 2020.
Notice of Allowance for U.S. Appl. No. 15/221,106 mailed May 1, 2019.
Notice of Allowance for U.S. Appl. No. 15/238,427 mailed May 23, 2019.
Notice of Allowance for U.S. Appl. No. 15/260,103 mailed Jun. 7, 2019.
Notice of Allowance for U.S. Appl. No. 15/611,587 mailed Dec. 21, 2018.
Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Feb. 19, 2021.
Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Jan. 21, 2021.
Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Aug. 5, 2021.
Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Nov. 24, 2021.
Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Nov. 26, 2021.
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Apr. 28, 2021.
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Jul. 10, 2020.
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed May 14, 2020.
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Sep. 29, 2020.
Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Apr. 29, 2021.
Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Jan. 29, 2021.
Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Oct. 16, 2020.
Notice to File Missing Parts for U.S. Appl. No. 17/179,116 mailed Mar. 3, 2021.
Restriction Requirement for U.S. Appl. No. 16/433,773 mailed Dec. 7, 2021.
Restriction Requirement for U.S. Appl. No. 16/478,180 mailed May 25, 2021.
U.S. Appl. No. 14/433,773, filed Apr. 3, 2020.
U.S. Appl. No. 14/625,469, filed Feb. 28, 2015.
U.S. Appl. No. 14/947,759, filed Nov. 20, 2015.
U.S. Appl. No. 14/952,591, filed Nov. 25, 2015.
U.S. Appl. No. 15/171,968, filed Jun. 2, 2016.
U.S. Appl. No. 15/221,106, filed Jul. 27, 2016.
U.S. Appl. No. 15/260,103, filed Sep. 8, 2016.
U.S. Appl. No. 15/611,587, filed Jun. 1, 2017.
U.S. Appl. No. 15/612,325, filed Jun. 2, 2017.
U.S. Appl. No. 16/245,726, filed Jan. 11, 2019.
U.S. Appl. No. 16/369,676, filed Mar. 29, 2019.
U.S. Appl. No. 16/433,773, filed Jun. 6, 2019.
U.S. Appl. No. 16/449,039, filed Jun. 21, 2019.
U.S. Appl. No. 16/452,145, filed Jun. 25, 2019.
U.S. Appl. No. 16/452,258, filed Jun. 25, 2019.
U.S. Appl. No. 16/478,180, filed Jul. 16, 2019.
U.S. Appl. No. 16/904,868, filed Jun. 18, 2020.
U.S. Appl. No. 16/905,400, filed Jun. 18, 2020.
U.S. Appl. No. 17/051,550, filed Oct. 29, 2020.
U.S. Appl. No. 17/051,554, filed Oct. 29, 2020.
U.S. Appl. No. 17/051,585, filed Oct. 29, 2020.
U.S. Appl. No. 17/051,600, filed Oct. 29, 2020.
U.S. Appl. No. 17/088,272, filed Nov. 3, 2020.
U.S. Appl. No. 17/179,116, filed Feb. 18, 2021.
U.S. Appl. No. 17/330,657, filed May 26, 2021.
U.S. Appl. No. 17/378,015, filed Jul. 16, 2021.
U.S. Appl. No. 17/412,864, filed Aug. 26, 2021.
U.S. Appl. No. 17/444,825, filed Aug. 10, 2021.
U.S. Appl. No. 17/446,256, filed Aug. 27, 2021.
U.S. Appl. No. 17/446,654, filed Sep. 1, 2021.
U.S. Appl. No. 17/447,123, filed Sep. 8, 2021.
U.S. Appl. No. 17/450,864, filed Oct. 14, 2021.
U.S. Appl. No. 17/451,345, filed Oct. 19, 2021.
U.S. Appl. No. 17/451,354, filed Oct. 19, 2021.
U.S. Appl. No. 17/453,260, filed Nov. 2, 2021.
U.S. Appl. No. 17/453,560, filed Nov. 4, 2021.
U.S. Appl. No. 17/461,036 mailed Aug. 30, 2021.
U.S. Appl. No. 17/494,578, filed Oct. 5, 2021.
U.S. Appl. No. 17/501,591, filed Oct. 14, 2021.
U.S. Appl. No. 17/595,747, filed Nov. 23, 2021.
U.S. Appl. No. 17/614,173, filed Nov. 24, 2021.
U.S. Appl. No. 17/645,821, filed Dec. 23, 2021.
U.S. Appl. No. 29/741,751, filed Jul. 15, 2020.
U.S. Appl. No. 61/955,537, filed Mar. 19, 2014.
U.S. Appl. No. 62/082,279, filed Nov. 20, 2014.
U.S. Appl. No. 62/084,078, filed Nov. 25, 2014.
U.S. Appl. No. 62/414,963, filed Oct. 31, 2016.
U.S. Appl. No. 62/452,437, filed Jan. 31, 2017.
U.S. Appl. No. 62/485,578, filed Apr. 14, 2017.
U.S. Appl. No. 62/665,297, filed May 1, 2018.
U.S. Appl. No. 62/665,302, filed May 1, 2018.
U.S. Appl. No. 62/665,317, filed May 1, 2018.
U.S. Appl. No. 62/665,321, filed May 1, 2018.
U.S. Appl. No. 62/665,331, filed May 1, 2018.
U.S. Appl. No. 62/665,335, filed May 1, 2018.
U.S. Appl. No. 62/853,279, filed May 28, 2019.
U.S. Appl. No. 62/853,889, filed May 29, 2019.
U.S. Appl. No. 62/864,656, filed Jun. 21, 2019.
U.S. Appl. No. 62/873,045, filed Jul. 11, 2019.
U.S. Appl. No. 62/873,048, filed Jul. 11, 2019.
U.S. Appl. No. 62/876,500, filed Jul. 19, 2019.
U.S. Appl. No. 62/877,558, filed Jul. 23, 2019.
U.S. Appl. No. 62/883,172, filed Aug. 6, 2019.
U.S. Appl. No. 62/889,149, filed Aug. 20, 2019.
U.S. Appl. No. 62/938,447, filed Nov. 21, 2019.
U.S. Appl. No. 62/949,187, filed Dec. 17, 2019.
U.S. Appl. No. 62/956,756, filed Jan. 3, 2020.
U.S. Appl. No. 62/956,767, filed Jan. 3, 2020.
U.S. Appl. No. 62/956,770, filed Jan. 3, 2020.
U.S. Appl. No. 62/994,912, filed Mar. 26, 2020.
U.S. Appl. No. 63/011,445, filed Apr. 17, 2020.
U.S. Appl. No. 63/011,487, filed Apr. 17, 2020.
U.S. Appl. No. 63/011,571, filed Apr. 17, 2020.
U.S. Appl. No. 63/011,657, filed Apr. 17, 2020.
U.S. Appl. No. 63/011,760, filed Apr. 17, 2020.
U.S. Appl. No. 63/012,347, filed Apr. 20, 2020.
U.S. Appl. No. 63/012,384, filed Apr. 20, 2020.
U.S. Appl. No. 63/030,685, filed May 27, 2020.
U.S. Appl. No. 63/033,310, filed Jun. 2, 2020.
U.S. Appl. No. 63/047,374, filed Jul. 2, 2020.
U.S. Appl. No. 63/061,241, filed Aug. 5, 2020.
U.S. Appl. No. 63/061,244, filed Aug. 5, 2020.
U.S. Appl. No. 63/061,834, filed Aug. 6, 2020.
U.S. Appl. No. 63/064,017, filed Aug. 11, 2020.
U.S. Appl. No. 63/064,126, filed Aug. 11, 2020.
U.S. Appl. No. 63/067,542, filed Aug. 19, 2020.
U.S. Appl. No. 63/071,438, filed Aug. 28, 2020.
U.S. Appl. No. 63/071,821, filed Aug. 28, 2020.
U.S. Appl. No. 63/073,545, filed Sep. 2, 2020.
U.S. Appl. No. 63/073,553, filed Sep. 2, 2020.
U.S. Appl. No. 63/074,051, filed Sep. 3, 2020.
U.S. Appl. No. 63/074,066, filed Sep. 3, 2020.
U.S. Appl. No. 63/076,032, filed Sep. 9, 2020.
U.S. Appl. No. 63/076,474, filed Sep. 10, 2020.
U.S. Appl. No. 63/076,477, filed Sep. 10, 2020.
U.S. Appl. No. 63/082,261, filed Sep. 23, 2020.
U.S. Appl. No. 63/088,506, filed Oct. 7, 2020.
U.S. Appl. No. 63/088,511, filed Oct. 7, 2020.
U.S. Appl. No. 63/088,539, filed Oct. 7, 2020.
U.S. Appl. No. 63/094,464, filed Oct. 21, 2020.
U.S. Appl. No. 63/094,498, filed Oct. 21, 2020.
U.S. Appl. No. 63/094,594, filed Oct. 21, 2020.
U.S. Appl. No. 63/094,608, filed Oct. 21, 2020.
U.S. Appl. No. 63/094,626, filed Oct. 21, 2020.
U.S. Appl. No. 63/109,066, filed Nov. 3, 2020.
U.S. Appl. No. 63/109,084, filed Nov. 3, 2020.
U.S. Appl. No. 63/112,417, filed Nov. 11, 2020.
U.S. Appl. No. 63/119,161, filed Nov. 30, 2020.
U.S. Appl. No. 63/124,271, filed Dec. 11, 2020.
U.S. Appl. No. 63/133,892, filed Jan. 5, 2021.
U.S. Appl. No. 63/134,287, filed Jan. 6, 2021.
U.S. Appl. No. 63/134,450, filed Jan. 6, 2021.
U.S. Appl. No. 63/134,631, filed Jan. 7, 2021.
U.S. Appl. No. 63/134,632, filed Jan. 7, 2021.
U.S. Appl. No. 63/134,754, filed Jan. 7, 2021.
U.S. Appl. No. 63/146,946, filed Feb. 8, 2021.
U.S. Appl. No. 63/147,013, filed Feb. 8, 2021.
U.S. Appl. No. 63/147,299, filed Feb. 9, 2021.
U.S. Appl. No. 63/148,723, filed Feb. 12, 2021.
U.S. Appl. No. 63/154,248, filed Feb. 26, 2021.
U.S. Appl. No. 63/155,395, filed Mar. 2, 2021.
U.S. Appl. No. 63/157,007, filed Mar. 5, 2021.
U.S. Appl. No. 63/157,014, filed Mar. 5, 2021.
U.S. Appl. No. 63/159,142, filed Mar. 10, 2021.
U.S. Appl. No. 63/159,186, filed Mar. 10, 2021.
U.S. Appl. No. 63/159,210, filed Mar. 10, 2021.
U.S. Appl. No. 63/159,280, filed Mar. 10, 2021.
U.S. Appl. No. 63/165,273, filed Mar. 24, 2021.
U.S. Appl. No. 63/165,384, filed Mar. 24, 2021.
U.S. Appl. No. 63/171,165, filed Apr. 6, 2021.
U.S. Appl. No. 63/172,975, filed Apr. 9, 2021.
U.S. Appl. No. 63/181,695, filed Apr. 29, 2021.
U.S. Appl. No. 63/192,274, filed May 24, 2021.
U.S. Appl. No. 63/193,235, filed May 26, 2021.
U.S. Appl. No. 63/193,406, filed May 26, 2021.
U.S. Appl. No. 63/193,891, filed May 27, 2021.
U.S. Appl. No. 63/214,551, filed Jun. 24, 2021.
U.S. Appl. No. 63/214,570, filed Jun. 24, 2021.
U.S. Appl. No. 63/215,017, filed Jun. 25, 2021.
U.S. Appl. No. 63/228,244, filed Aug. 2, 2021.
U.S. Appl. No. 63/228,252, filed Aug. 2, 2021.
U.S. Appl. No. 63/228,258, filed Aug. 2, 2021.
U.S. Appl. No. 63/230,894, filed Aug. 9, 2021.
U.S. Appl. No. 63/238,457, filed Aug. 30, 2021.
U.S. Appl. No. 63/238,477, filed Aug. 30, 2021.
U.S. Appl. No. 63/241,562, filed Sep. 8, 2021.
U.S. Appl. No. 63/241,564, filed Sep. 8, 2021.
U.S. Appl. No. 63/241,575, filed Sep. 8, 2021.
U.S. Appl. No. 63/246,972, filed Sep. 22, 2021.
U.S. Appl. No. 63/247,375, filed Sep. 23, 2021.
U.S. Appl. No. 63/247,478, filed Sep. 23, 2021.
U.S. Appl. No. 63/247,491, filed Sep. 23, 2021.
Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and 10,376,407, 292 pages.
Plaintiff's Identification of Claim Terms and Proposed Constructions, 3 pages.
Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and 10,376,407, 7 pages.
Corrected Certificate of Service, 2020, 2 pages.
Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages.
Declaration of Diane K. Newman Curriculum Vitae, 2020, pp. 1-199.
Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages.
Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Feb. 17, 2021, 39 pages.
Memorandum Order, Feb. 2021, 14 pgs.
Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs.
PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Mar. 23, 2020, 6 pages.
Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and 10,390,989, May 29, 2020, 193 pages.
Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, Nov. 1, 2019.
Plaintiff's Opening Claim Construction Brief, Oct. 16, 2020, 26 pages.
“3 Devices Take Top Honors in Dare-To-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page.
“Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages.
“AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, 8 pages.
“AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015.
“AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, 2 pages.
“External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages.
“High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages.
“How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages.
“Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages.
“In Flight Bladder Relief”, Omni Medical, 14 pages.
“Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages.
“Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages.
“Research and Development Work Relating to Assistive Technology Jun. 2005”, British Department of Health, Nov. 2006, 40 pages.
“Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, Aug. 30, 2017, 4 pages.
“Underwear that absorbs your period”, Thinx!, 7 pages.
“User & Maintenance Guide”, Omni Medical, 2007, 16 pages.
“Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, 2014, 4 pages.
Hollister , Female Urinary and Pouch and Male Urinary Pouch Brochure, 2011, 1 page.
Hollister , “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device.
Hollister , “Retracted Penis Pouch by Hollister”, Vitality Medical.com, 6 pages.
Macaulay , et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, 2007, pp. 641-648.
Newman , et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages.
Newton , et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages.
Parmar , “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages.
Purewick , “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages.
Pytlik , “Super Absorbent Polymers”, University of Buffalo.
Sachtman , “New Relief for Pilots? It Depends”, Wired, 2008, 2 pages.
Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 7, 2023.
Advisory Action for U.S. Appl. No. 17/051,550 mailed Sep. 8, 2023.
Advisory Action for U.S. Appl. No. 17/444,792 mailed Aug. 25, 2023.
Final Office Action for U.S. Appl. No. 16/369,676 mailed Aug. 31, 2023.
Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 27, 2023.
Final Office Action for U.S. Appl. No. 17/444,792 mailed Jun. 15, 2023.
Final Office Action for U.S. Appl. No. 17/446,256 mailed Sep. 19, 2023.
Final Office Action for U.S. Appl. No. 17/448,811 mailed Aug. 3, 2023.
Final Office Action for U.S. Appl. No. 17/653,137 mailed Sep. 21, 2023.
Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/043818 mailed Mar. 24, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/044208 mailed May 8, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/049300 mailed Jun. 6, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2022/050909 mailed Jul. 24, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2023/012696 mailed Jul. 6, 2023.
Non-Final Office Action for U.S. Appl. No. 17/051,399 mailed Aug. 18, 2023.
Non-Final Office Action for U.S. Appl. No. 17/326,980 mailed Jul. 11, 2023.
Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Sep. 8, 2023.
Non-Final Office Action for U.S. Appl. No. 17/657,474 mailed Sep. 12, 2023.
Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed Jul. 6, 2023.
Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jun. 29, 2023.
Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 8, 2023.
Non-Final Office Action for U.S. Appl. No. 18/139,523 mailed Aug. 17, 2023.
Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Sep. 14, 2023.
Notice of Allowance for U.S. Appl. No. 16/245,726 mailed Jul. 6, 2023.
Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Jul. 6, 2023.
Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Jun. 30, 2023.
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jul. 28, 2023.
Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Jul. 24, 2023.
Restriction Requirement for U.S. Appl. No. 17/051,600 mailed Sep. 21, 2023.
Restriction Requirement for U.S. Appl. No. 17/645,821 mailed Jul. 12, 2023.
Restriction Requirement for U.S. Appl. No. 17/657,474 mailed Jun. 30, 2023.
U.S. Appl. No. 17/664,487, filed May 23, 2022.
U.S. Appl. No. 18/259,626, filed Jun. 28, 2023.
U.S. Appl. No. 18/260,122 filed Jun. 30, 2023.
U.S. Appl. No. 18/260,391, filed Jul. 5, 2023.
U.S. Appl. No. 18/260,394, filed Jul. 5, 2023.
U.S. Appl. No. 18/263,800, filed Aug. 1, 2023.
U.S. Appl. No. 18/264,004, filed Aug. 2, 2023.
U.S. Appl. No. 18/265,736, filed Jun. 7, 2023.
U.S. Appl. No. 18/335,579, filed Jun. 15, 2023.
U.S. Appl. No. 18/373,424, filed Sep. 27, 2023.
U.S. Appl. No. 18/376,274, filed Oct. 3, 2023.
U.S. Appl. No. 18/548,152, filed Aug. 28, 2023.
U.S. Appl. No. 18/549,387, filed Sep. 7, 2023.
U.S. Appl. No. 18/553,625, filed Oct. 2, 2023.
U.S. Appl. No. 63/150,640, filed Feb. 18, 2021.
Merriam-Webster Dictionary, , “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/ embed last accessed Aug. 3, 2023, 2003.
Advisory Action for U.S. Appl. No. 16/433,773 mailed Dec. 29, 2023.
Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024.
Advisory Action for U.S. Appl. No. 16/904,868 mailed Jan. 2, 2024.
Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 17, 2023.
Advisory Action for U.S. Appl. No. 17/179,116 mailed Jan. 8, 2024.
Advisory Action for U.S. Appl. No. 17/446,256 mailed Dec. 8, 2023.
Advisory Action for U.S. Appl. No. 17/448,811 mailed Nov. 15, 2023.
Advisory Action for U.S. Appl. No. 17/451,345 mailed Oct. 20, 2023.
Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024.
Advisory Action for U.S. Appl. No. 17/453,260 mailed Dec. 22, 2023.
Advisory Action for U.S. Appl. No. 17/501,591 mailed Feb. 22, 2024.
Advisory Action for U.S. Appl. No. 17/653,137 mailed Dec. 1, 2023.
Advisory Action for U.S. Appl. No. 17/655,464 mailed Dec. 13, 2023.
Advisory Action for U.S. Appl. No. 17/661,090 mailed Feb. 26, 2024.
Advisory Action for U.S. Appl. No. 17/663,330 mailed Feb. 27, 2024.
Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024.
Communication of Notice of Opposition of European Application No. 17807547.9 mailed Jan. 5, 2024.
Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 mailed Dec. 7, 2023.
Corrected Notice of Allowability for U.S. Appl. No. 17/326,980 mailed Feb. 8, 2024.
Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 10, 2023.
Final Office Action for U.S. Appl. No. 16/449,039 mailed Nov. 21, 2023.
Final Office Action for U.S. Appl. No. 16/452,258 mailed Dec. 21, 2023.
Final Office Action for U.S. Appl. No. 16/478,180 mailed Feb. 28, 2024.
Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 2, 2023.
Final Office Action for U.S. Appl. No. 17/051,399 mailed Jan. 8, 2024.
Final Office Action for U.S. Appl. No. 17/179,116 mailed Oct. 31, 2023.
Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024.
Final Office Action for U.S. Appl. No. 17/450,864 mailed Dec. 28, 2023.
Final Office Action for U.S. Appl. No. 17/451,354 mailed Oct. 30, 2023.
Final Office Action for U.S. Appl. No. 17/453,260 mailed Oct. 5, 2023.
Final Office Action for U.S. Appl. No. 17/501,591 mailed Nov. 14, 2023.
Final Office Action for U.S. Appl. No. 17/661,090 mailed Dec. 11, 2023.
Final Office Action for U.S. Appl. No. 17/663,330 mailed Dec. 12, 2023.
Final Office Action for U.S. Appl. No. 17/664,487 mailed Jan. 4, 2024.
Final Office Action for U.S. Appl. No. 18/139,523 mailed Dec. 22, 2023.
Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024.
Final Office Action for U.S. Appl. No. 18/164,800 mailed Dec. 6, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2023/018474 mailed Sep. 11, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2023/024805 mailed Dec. 14, 2023.
International Search Report and Written Opinion from International Application No. PCT/US2023/025192 mailed Feb. 7, 2024.
Issue Notification for U.S. Appl. No. 16/245,726 mailed Oct. 18, 2023.
Issue Notification for U.S. Appl. No. 17/051,554 mailed Mar. 6, 2024.
Issue Notification for U.S. Appl. No. 17/461,036 mailed Oct. 11, 2023.
Issue Notification for U.S. Appl. No. 17/663,046 mailed Dec. 20, 2023.
Issue Notification for U.S. Appl. No. 18/299,788 mailed Feb. 21, 2024.
Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Feb. 29, 2024.
Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Feb. 26, 2024.
Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Nov. 2, 2023.
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Nov. 7, 2023.
Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Oct. 24, 2023.
Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Jan. 8, 2024.
Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024.
Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Feb. 26, 2024.
Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Nov. 17, 2023.
Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024.
Non-Final Office Action for U.S. Appl. No. 17/447,123 mailed Jan. 24, 2024.
Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024.
Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024.
Non-Final Office Action for U.S. Appl. No. 17/453,560 mailed Oct. 16, 2023.
Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Oct. 25, 2023.
Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Jan. 18, 2024.
Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024.
Non-Final Office Action for U.S. Appl. No. 17/808,354 mailed Nov. 28, 2023.
Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024.
Non-Final Office Action for U.S. Appl. No. 18/140,163 mailed Nov. 9, 2023.
Non-Final Office Action for U.S. Appl. No. 18/198,464 mailed Dec. 7, 2023.
Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Nov. 14, 2023.
Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024.
Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Oct. 18, 2023.
Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Jan. 29, 2024.
Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024.
Notice of Allowance for U.S. Appl. No. 17/657,474 mailed Mar. 5, 2024.
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 6, 2024.
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Nov. 15, 2023.
Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Nov. 6, 2023.
Restriction Requirement for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2023.
Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024.
Supplemental Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 21, 2024.
Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024.
U.S. Appl. No. 17/451,719, filed Oct. 19, 2021.
U.S. Appl. No. 18/294,370, filed Feb. 1, 2024.
U.S. Appl. No. 18/294,403, filed Feb. 1, 2024.
U.S. Appl. No. 18/389,009, filed Nov. 13, 2023.
U.S. Appl. No. 18/415,080, filed Jan. 17, 2024.
U.S. Appl. No. 18/426,795, filed Jan. 30, 2024.
U.S. Appl. No. 18/549,658, filed Sep. 8, 2023.
U.S. Appl. No. 18/556,945, filed Oct. 24, 2023.
U.S. Appl. No. 18/558,502, filed Nov. 1, 2023.
U.S. Appl. No. 18/562,626, filed Nov. 20, 2023.
U.S. Appl. No. 18/563,672, filed Nov. 22, 2023.
U.S. Appl. No. 18/569,711, filed Dec. 13, 2023.
U.S. Appl. No. 18/569,778, filed Dec. 13, 2023.
U.S. Appl. No. 18/584,002, filed Feb. 22, 2024.
U.S. Appl. No. 18/681,987, filed Feb. 7, 2024.
U.S. Appl. No. 18/682,006, filed Feb. 7, 2024.
U.S. Appl. No. 18/687,117, filed Feb. 27, 2024.
U.S. Appl. No. 18/688,023, filed Feb. 29, 2024.
U.S. Appl. No. 63/596,012, filed Nov. 3, 2023.
U.S. Appl. No. 63/608,553, filed Dec. 11, 2023.
Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016, 7 pages.
Advisory Action for U.S. Appl. No. 16/452,258 mailed Apr. 8, 2024.
Advisory Action for U.S. Appl. No. 16/478,180 mailed Jun. 7, 2024.
Advisory Action for U.S. Appl. No. 17/444,792 mailed Jul. 8, 2024.
Advisory Action for U.S. Appl. No. 17/446,654 mailed Apr. 15, 2024.
Advisory Action for U.S. Appl. No. 17/450,864 mailed Mar. 21, 2024.
Advisory Action for U.S. Appl. No. 17/451,345 mailed Jul. 3, 2024.
Advisory Action for U.S. Appl. No. 17/645,821 mailed Jul. 2, 2024.
Advisory Action for U.S. Appl. No. 17/664,487 mailed Mar. 13, 2024.
Advisory Action for U.S. Appl. No. 17/808,354 mailed Jun. 12, 2024.
Advisory Action for U.S. Appl. No. 18/139,523 mailed Apr. 24, 2024.
Advisory Action for U.S. Appl. No. 18/140,163 mailed Jun. 3, 2024.
Advisory Action for U.S. Appl. No. 18/140,751 mailed Apr. 24, 2024.
Corrected Notice of Allowability for U.S. Appl. No. 17/501,591 mailed Aug. 9, 2024.
Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed Mar. 13, 2024.
Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed May 14, 2024.
Corrected Notice of Allowability for U.S. Appl. No. 17/664,914 mailed Aug. 9, 2024.
Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 5, 2024.
Final Office Action for U.S. Appl. No. 17/051,600 mailed Jun. 27, 2024.
Final Office Action for U.S. Appl. No. 17/444,792 mailed Apr. 3, 2024.
Final Office Action for U.S. Appl. No. 17/446,256 mailed Aug. 7, 2024.
Final Office Action for U.S. Appl. No. 17/447,123 mailed May 14, 2024.
Final Office Action for U.S. Appl. No. 17/451,345 mailed Apr. 18, 2024.
Final Office Action for U.S. Appl. No. 17/645,821 mailed Apr. 3, 2024.
Final Office Action for U.S. Appl. No. 17/653,137 mailed Aug. 7, 2024.
Final Office Action for U.S. Appl. No. 17/653,920 mailed Aug. 14, 2024.
Final Office Action for U.S. Appl. No. 17/808,354 mailed Apr. 10, 2024.
Final Office Action for U.S. Appl. No. 18/134,857 mailed Jul. 25, 2024.
Final Office Action for U.S. Appl. No. 18/140,163 mailed Mar. 27, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/025939 mailed Feb. 7, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/030365 mailed Mar. 13, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/030373 mailed Mar. 13, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/031433 mailed Mar. 4, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/031740 mailed Mar. 4, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/036238 mailed Jul. 22, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/036868 mailed Jun. 5, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/075507 mailed Jun. 13, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/077168 mailed Jun. 24, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/077208 mailed May 10, 2024.
International Search Report and Written Opinion from International Application No. PCT/US2023/080680 mailed Jul. 22, 2024.
Issue Notification for U.S. Appl. No. 16/449,039 mailed Jun. 19, 2024.
Issue Notification for U.S. Appl. No. 17/051,550 mailed Mar. 13, 2024.
Issue Notification for U.S. Appl. No. 17/326,980 mailed Jul. 10, 2024.
Issue Notification for U.S. Appl. No. 17/448,811 mailed Jul. 3, 2024.
Issue Notification for U.S. Appl. No. 17/453,260 mailed Jul. 10, 2024.
Issue Notification for U.S. Appl. No. 17/453,560 mailed Aug. 7, 2024.
Issue Notification for U.S. Appl. No. 17/657,474 mailed Jun. 19, 2024.
Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 20, 2024.
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Aug. 7, 2024.
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 12, 2024.
Non-Final Office Action for U.S. Appl. No. 17/378,015 mailed Jul. 5, 2024.
Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Jun. 25, 2024.
Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 29, 2024.
Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jul. 25, 2024.
Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed Apr. 4, 2024.
Non-Final Office Action for U.S. Appl. No. 17/595,747 mailed Jun. 7, 2024.
Non-Final Office Action for U.S. Appl. No. 17/597,408 mailed Aug. 15, 2024.
Non-Final Office Action for U.S. Appl. No. 17/597,673 mailed Mar. 20, 2024.
Non-Final Office Action for U.S. Appl. No. 17/653,920 mailed Mar. 15, 2024.
Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 26, 2024.
Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed May 22, 2024.
Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jul. 1, 2024.
Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 17, 2024.
Non-Final Office Action for U.S. Appl. No. 17/749,340 mailed Aug. 14, 2024.
Non-Final Office Action for U.S. Appl. No. 18/003,029 mailed Mar. 26, 2024.
Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Jun. 21, 2024.
Non-Final Office Action for U.S. Appl. No. 18/164,800 mailed Mar. 22, 2024.
Non-Final Office Action for U.S. Appl. No. 18/389,009 mailed May 24, 2024.
Non-Final Office Action for U.S. Appl. No. 18/426,795 mailed Aug. 9, 2024.
Non-Final Office Action for U.S. Appl. No. 18/451,080 mailed Jul. 30, 2024.
Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Jun. 17, 2024.
Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Mar. 28, 2024.
Notice of Allowance for U.S. Appl. No. 16/452,145 mailed Jul. 11, 2024.
Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Apr. 5, 2024.
Notice of Allowance for U.S. Appl. No. 17/447,123 mailed Jul. 26, 2024.
Notice of Allowance for U.S. Appl. No. 17/448,811 mailed Jun. 14, 2024.
Notice of Allowance for U.S. Appl. No. 17/453,260 mailed Apr. 8, 2024.
Notice of Allowance for U.S. Appl. No. 17/501,591 mailed Jul. 31, 2024.
Notice of Allowance for U.S. Appl. No. 17/657,474 mailed May 2, 2024.
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jun. 12, 2024.
Notice of Allowance for U.S. Appl. No. 17/664,914 mailed Jul. 26, 2024.
Notice of Allowance for U.S. Appl. No. 18/140,163 mailed Aug. 21, 2024.
Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Apr. 17, 2024.
Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Jul. 30, 2024.
Restriction Requirement for U.S. Appl. No. 17/527,769 mailed Jun. 17, 2024.
Restriction Requirement for U.S. Appl. No. 17/625,941 mailed Aug. 7, 2024.
Restriction Requirement for U.S. Appl. No. 17/667,097 mailed Mar. 20, 2024.
U.S. Appl. No. 17/013,822, filed Sep. 7, 2020.
U.S. Appl. No. 17/444,792, filed Aug. 10, 2021.
U.S. Appl. No. 18/249,577, filed Oct. 19, 2021.
U.S. Appl. No. 18/610,523, filed Mar. 20, 2024.
U.S. Appl. No. 18/662,216, filed May 13, 2024.
U.S. Appl. No. 18/693,638, filed Mar. 20, 2024.
U.S. Appl. No. 18/694,090, filed Mar. 21, 2024.
U.S. Appl. No. 18/728,604, filed Jul. 12, 2024.
U.S. Appl. No. 18/757,964, filed Jun. 28, 2024.
U.S. Appl. No. 18/758,025, filed Jun. 28, 2024.
U.S. Appl. No. 18/834,115, filed Jul. 29, 2024.
U.S. Appl. No. 18/834,176, filed Jul. 29, 2024.
U.S. Appl. No. 18/834,340, filed Jul. 30, 2024.
U.S. Appl. No. 18/835,068, filed Aug. 1, 2024.
U.S. Appl. No. 18/835,444, filed Aug. 2, 2024.
U.S. Appl. No. 18/836,204, filed Aug. 6, 2024.
U.S. Appl. No. 63/561,893, filed Dec. 11, 2023.
U.S. Appl. No. 63/568,615, filed Mar. 22, 2024.
U.S. Appl. No. 63/683,428, filed Aug. 15, 2024.
“OBLONG”, Cambridge Dictionary, https://dictionary.cambridge.org/dictionary/english/oblong, 2024, 1 page.
Britannica, “Polyolefin”, Britannica Online Encyclopedia, T. Editors of Encyclopaedia, https://www.britannica.com/science/polyolefin, Jul. 26, 2012.
Martin, et al., “Chapter 5 Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices”, Hydrophilic Matrix Tablets for Oral Controlled Release, AAPS Advances in the Pharmaceutical Sciences vol. 16, 2014, pp. 123-141.
Wikipedia Article, “Decibel”, https://web.archive.org/web/2020041521917/https://en.wikipedia/org/wiki/Decibel last accessed Mar. 11, 2024, 21 pages.
Wikipedia Article, “Fiberglass”, https://web.archive.org.web/20200309194847/https://en.wikipedia.org/wiki/Fiberglass last accessed Mar. 11, 2024.
Related Publications (1)
Number Date Country
20220211536 A1 Jul 2022 US
Provisional Applications (1)
Number Date Country
63134450 Jan 2021 US